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ABSTRACT OF THE DISSERTATION
Developing an Induction Protocol and Generating a Selectable Cell Line
to Obtain High-Purity V0V Interneuron Cultures from Mouse Embryonic Stem Cells
by
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Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2021
Professor Dennis Barbour, Chair
Professor Shelly Sakiyama-Elbert, Co-Chair

Spinal cord injury (SCI) leads to loss of motor function among other devastating
impairments, with patients having a grim outlook on recovery as currently there are no widely
efficacious treatment methods. The native regenerative capacity of the neurons in the central
nervous system is limited, thus recovery of the axonal connections between the different
components of the complex circuitry that enables motor function is minimal after SCI.
Investigators aiming to improve motor function post-SCI approach the problem from different
angles, including removing inhibitory elements to axonal regeneration and supporting
regeneration through implantation of biomaterials, exposure to pro-regenerative factors, and
x

transplantation of cells. For cell transplantation, populations to consider include the spinal
interneurons (INs), with the ventral IN (vIN) subtypes known to have roles in motor circuits and
having previously been shown to contribute to functional recovery in rodent SCI models. Among
the vINs, those that release excitatory neurotransmitters are especially of interest for regenerative
therapies, as they can lead to motor neuron stimulation and thus functional output. One vIN
subtype is the V0 INs, which are diverse, largely with commissurally projecting-axons, and
broadly include a dorsal, inhibitory population - V0D INs - and a ventral, excitatory population V0V INs. To obtain a sufficient number of INs for further study and transplantation, deriving
them by differentiating pluripotent stem cells (PSCs) is practical method. However, induction
protocols yield heterogenous cultures, and thus a means of selecting the desired population is
necessary. One selection method involves creating a transgenic PSC line by inserting an
antibiotic resistance gene into a cell-specific gene locus. This dissertation will include work on
deriving the V0V IN population from a PSC source, mouse embryonic stem cells, and generating
a transgenic mouse embryonic stem cell line to enable selection of V0V INs from induced
cultures, thus providing tools for future investigations using V0V INs as a therapeutic,
transplantable population.

xi

Chapter 1: Introduction
1.1 Overview
This dissertation will discuss my work on using mouse embryonic stem cells (mESCs) to derive
a spinal interneuron (IN) population, the V0V INs, and generating a transgenic mESC line as a
tool to study high-purity V0V INs with the aim of their use as a therapeutic, transplantable
population in spinal cord injury (SCI). This document first briefly introduces SCI, then the
neuronal populations that are involved in motor function spinal circuits are laid out, with a focus
on vINs due to their role in local, spontaneous recovery post-SCI in animal models. Pluripotent
stem cells (PSCs) are discussed as a source for vINs to enable high-throughput, efficient
generation of the population of interest, such as using mouse embryonic stem cells (mESCs) to
derive V0V INs. Following this, genetic manipulation of PSCs and neurons, including
modifications to enable isolation of a high-purity V0V IN population from a mESC-derived
heterogenous culture, is covered. Uses for such genetically manipulated cells is considered, as
tools both in research and in the clinic.

The vINs have been shown to be part of spinal circuitry that contribute to many rhythm-driven
movements including locomotion, which is a function that, if regained, would improve SCI
patients’ quality of life. One of the vIN populations is the V0 INs, and among them, the ventral
V0 (V0V) INs are an excitatory population that wires both sides of the cord. However, there is
still work needed to fully characterize the V0 IN subpopulations including the V0V INs and their
roles in spinal circuits and as a potential therapeutic population. Therefore, a means of obtaining
1

a large number of V0V INs would enhance researchers’ ability to complete such work. One
possibility for obtaining sufficient numbers of vINs is to derive them from a PSC source.

PSCs, including patient-derived induced PSCs (iPSCs), and mESCs have been used previously to
derive vIN populations. Using PSCs as a renewable, scalable source is useful for obtaining a
large number of the relatively small proportion of cells that make up each vIN population in the
spinal cord without having to sacrifice animals (for research) and which is, at the very least,
impractical in patients. To induce mESCs, some aspects of neural development can be
recapitulated in vitro, and following what is known about V0V IN generation and the expression
of transcription factor markers for V0V INs and their progenitors helped guide development of an
induction protocol to generate V0V INs. However, deriving any population of PSCs results in a
heterogenous culture, which can diminish their utility when isolated populations are desired for
research or therapeutic applications. Therefore, a means of purifying the population of interest
from the mixture is necessary.

Genetic manipulation of PSCs can augment their usefulness as tools, including allowing users to
obtain a high-purity population of vINs from a PSC-derived induction. Modification can also
allow for identification or tracing of particular populations, enable activation/inactivation and
monitoring of neuronal activity by integrating effector or sensor proteins, or change gene
expression to alter protein expression, and consequently neuronal, function. Genetic changes can
be made by viral or non-viral means, including nuclease-based gene editing such as
CRISPR/Cas9, and considerations for introducing the change should be carefully considered
depending on factors including the desired target population and efficiency. Uses for genetically
manipulated cells is discussed, such as using a purified population of V0V INs in microelectrode
2

arrays (MEAs) to observe their contribution in simplified circuits or in vivo as a transplanted
population to potentially improve motor function in an SCI model.

1.2 A Brief Look at Spinal Cord Injury
Spinal cord injury (SCI) is devastating because of the importance of the spinal cord to our bodily
functions, as it relays messages between the body and the brain. Patients might want to give
someone a high five, go for a swim, kick a ball at their feet, or breathe normally, but depending
on the severity and location of the injury to their cords, these tasks and many others might no
longer be possible for them. In addition to bone, vasculature, and other tissues in the spinal
column, the injury damages the neurons in the cord and severs their axonal connections, thus
disrupting the body-brain relay. Often, the more rostral, or near the brain, the injury occurs, the
more body functions are lost. Cervical (neck) level injuries are most common, frequently leading
to tetraplegia in patients [1], many of whom require ventilators to breathe. Unfortunately, the
loss of body functions is often permanent, as the mature neurons in central nervous system
(CNS) tissues are intrinsically poor at regeneration; however, sprouting has been observed postinjury, but due to extrinsic factors such as the growth-inhibitory nature of the injury lesion,
sprouts retract and axons suffer dieback [2–5]. When functional recovery is observed in SCI
models, rewiring of several CNS centers such as cortical, supraspinal, and intraspinal circuits is
observed in conjunction, lending to the importance that SCI therapies address more than one
facet of recovery in parallel [6,7]. Addressing multiple facets requires an understanding of the
different components and how they contribute to recovery of body functions. Patient surveys
have shown that regaining motor function has remained a top priority for SCI patients, which has
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motivated research into the factors involved in regaining motor function and consideration and
application of such factors in SCI therapies [8–10].

1.3 Neurons in the CNS Involved in Loss of Motor Function
after SCI
After SCI, the loss of both motor and sensory functions is due to disrupted axonal connections in
the spinal cord. Regarding motor function, some of the cell populations to consider for
recovering function are therefore neurons that are involved in motor circuits with axons in the
spinal cord. This includes neurons of the medial and lateral descending tracts with cell bodies in
the brain and axonal projections in the spinal cord, the spinal motor neurons (MNs), with cell
bodies in the spinal cord and axonal projections exiting the cord through the ventral roots to
target muscles in the body, and the propriospinal interneurons (INs), with cell bodies and axonal
projections in the spinal cord. In this work, greater consideration is given to INs, as these can
potentially be used as populations directly transplanted into the injured spinal cord to recover
motor function through propriospinal connections; they are known to modulate activity of MNs
and have been shown to circumvent the injury lesion in some SCI models [11–13]. Currently,
transplantation of either the descending tract neurons or MNs is not practical, in part due to the
distance their axons would need to extend to reach their synaptic targets, thus these populations
are more relevant for discussion and investigation of neurotrophic support or axonal sprouting of
spared neurons for reestablishing connections. Therefore, in this document in which the focus is
on a cellular tool that can be used as a transplantable cell therapy, discussion of the descending
tracts and MNs will be covered briefly, owing to their association with motor output and
4

interaction with propriospinal INs, with more in-depth coverage of the ventral propriospinal IN
populations. Particular consideration will be given to a subpopulation of IN known to be
involved in locomotor circuits, the excitatory, ventral V0 (V0V) INs.

1.3.1 The Descending Motor Tracts

There are several descending motor tracts divided among what are broadly known as the medial
and lateral tracts. The medial tracts include the reticulospinal tract (RtST), vestibulospinal tract
(VST), tectospinal tract (TST), interstitiospinal tract (IST) and fastigiospinal tract, while the
lateral tracts include the corticospinal tract (CST) and rubrospinal tract (RbST) [14]. Knowing
where the tracts terminate (in studies examining these tracts, termination targets are often
mentioned in terms of laminae, which are the transverse, anatomical regions of the spinal cord,
as described by Rexed [15]) and their general contribution to motor function can enable some
understanding of their theoretical potential for regaining function if rewiring were to occur.
Something to have in mind is that ventral INs of locomotor networks reside in laminae VII, VIII,
and X while MNs are in lamina IX [16]. The medial tracts are largely involved in steering and
postural stability, with axonal projections extending bilaterally for most of their neurons; they
synapse onto INs near the ventral and medial areas of laminae VII-VIII and onto MNs
innervating neck, trunk, and limb muscles [14,17]. The lateral tracts are mainly involved in
controlling distal limb muscles through innervation of INs in lateral areas of laminae V–VI to
lamina VII [14].

The medial tracts are involved with more medial – generally, head to trunk - muscle control.
VST neurons have cell bodies in the brainstem with bilateral axonal projections as caudal as the
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lumbar spinal cord and are involved in postural control. Some VST neurons excite extensor MNs
and lead to inhibition of flexor MNs through Ia inhibitory INs (reciprocal inhibition), while
others have monosynaptic connections to MNs for neck and back muscles in the vestibulocollic
reflex (in which the head stabilizes when the body moves) [14]. The RtST cell bodies reside in
the brainstem with axonal projections terminating bilaterally, although the majority are
ipsilateral, in medial laminae VII and VIII and partly in lamina IX, and RtST neurons are
involved in preparation for movement and postural stability of medial trunk muscles [14,17]. The
TST axonal projections cross the midline just caudal to the superior colliculus of the midbrain,
from which it stems, reaching cervical cord laminae, while the bilaterally-projecting IST begins
from the nucleus of Cajal in the brainstem, synapsing onto the medial part of the upper cervical
ventral horn. The TST and IST neurons receive visual information and take part in eye and head
coordination for orienting responses [14]. Regarding recovery due to the medial tracts, RtST
neurons have been shown to form new axonal connections with propriospinal INs that form a
relay around the SCI lesion, accompanied by locomotor recovery, in rat SCI models [18–21].

Lateral tract neurons play roles in motor function of distal limbs. CST neuron cell bodies arise
from Layer V of the motor cortex and premotor areas of the brain and have extensive
contralateral synapses along the cord [14,17]. Some CST neurons directly innervate MNs of
distal limb muscle units, with others terminating in medial laminae VII–VIII. The cell bodies of
RbST neurons reside in the red nucleus of the midbrain with axonal projections synapsing
contralaterally in the intermediate gray matter regions of the cord: RbST neurons project axons
in laminae V–VII and IX. The lateral tracts contribute more to excitation of flexor muscles and
inhibition of extensor muscles and are known to synapse onto INs involved in central pattern
generators (CPG; see below, section 1.3.3 for more detail), such as V2a INs [7,14,17,22]. Many
6

studies involving recovery of motor function in injuries with spared tissue have found the CST
neurons sprout and form connections with RtST neurons and/or INs to form relay circuits in
rodent and primate models [6,23–30].

1.3.2 Motor Neurons

MNs are the efferent neurons of motor circuits that connect with muscles at neuromuscular
junctions to result in movement. They have cell bodies in the ventral horn of the spinal cord and
axonal projections that exit the cord through the ventral roots to terminate on striatal muscle
targets in the body. Studies investigating transplantation of MNs derived from pluripotent stem
cells (PSCs) have seen that they can extend axons through the ventral horn (of chick embryos)
and they can innervate muscle (of rats, when transplanted into adjacent nerve tissue), but no
studies have shown transplantation of MNs into cord tissue and subsequent innervation of striatal
muscle [31,32]. MN lineage cell transplantation instead offers a source of neurotrophic factors to
support cell survival and regrowth at the injury site [33,34]. An alternative approach to
transplantation for recovery of function using MNs is to promote collateral reinnervation of
muscle from adjacent motor units of spared MN axons or to use donor nerves with the same
objective, but recovery is limited due to the degree of innervation required to sufficiently
produce motor output [35]. Thus, MNs are of interest as a target population for connections of
transplanted or spared propriospinal or descending tract neurons, or in in vitro studies
investigating the interactions between these cell populations.

7

1.3.3 Propriospinal Interneurons

Propriospinal INs include the dorsal populations, which are involved in sensory relays, and the
ventral populations, which are involved in motor function [36]. This document will focus little
on the dorsal populations, although they are involved in reflexive motor circuits [37], as they are
more suited to discussions of recovering or modulating sensory information post-injury. The
exception are the dI6 INs, which have been found to be involved in locomotor networks [38–41].
The ventral INs include V3, V2, V1, and V0 cardinal classes, with various subpopulations and
contributions to motor function among each [16]. The ventral INs play a role in central pattern
generators (CPGs), which are the circuits that generate coordinated, rhythmic, repetitive motions
such as in locomotion, breathing, chewing, swimming, etc. [42,43]. For the locomotor CPG, leftright alternation and flexor-extensor alternation must be coordinated through the interactions of
the different contributing INs of the circuit [44]. These circuits also incorporate modulation to
increase or decrease motor output depending on the activity requirements [45].

The different IN populations arise from progenitors which are specified based on the presence of
different morphogens and the interplay between various signaling proteins during development.
As the neural tube forms, exposure to retinoic acid (RA) released from the adjacent somitic
mesoderm gives the spinal cord its caudal identity. The dorsal IN progenitor domains are defined
based on release of bone morphogenic proteins (BMPs) and Wnt family proteins from the roof
plate [46]. Likewise, the different ventral IN progenitor domains are defined based on a gradient
of sonic hedgehog (Shh), which is first released from the notochord and later from the floor
plate. Through cell-cell interactions, Notch/Delta signaling is also known to play a role in
population specification [47–49]. These signaling proteins activate or repress expression of
8

transcription factors which delineate the different progenitor domains. The transcription factors
expressed in the IN populations ultimately establish their defining characteristics including
neurotransmitter release, migration, and axonal extension toward their targets. Investigators have
used these defining transcription factors as markers for both the IN progenitors and for many of
the post-mitotic INs.

dI6 INs

The dI6 INs are an inhibitory population arising from Pax7+Pax2+Dbx2+ progenitors near the
dorsal, medial neural tube near the central canal. With mostly descending axons projecting
largely commissurally - some with ipsilateral projections – a proportion of dI6 INs have monoand di-synaptic inputs to MNs [38,40]. Markers for the different subpopulations have not been
fully characterized, but dI6 INs include Dmrt3+, Wt1+, Dmrt3+Wt1+ populations and an
additional proposed, uncharacterized population [38,40]. Dmrt3+ INs contribute commissural
projections, as Dmrt3-/- mice have fewer commissural neurons, and a loss of Dmrt3 results in
increased Wt1+ INs, suggesting an altered fate [38]. Dmrt3+ dI6 INs contribute to both right-left
and forelimb-hindlimb coordination [38,50], while Wt1+ dI6 INs are involved in left-right
alternation [51,52]. Further studies are needed to fully characterize and define the dI6
subpopulations, but they are of interest as an inhibitory modulating population since they have
been shown to contribute to the locomotor CPG. As such, recently, an induction protocol to
derive different dorsal populations, including dI6 INs, from human PSCs was developed [53].
This can aid investigators in future work with these cells.

V0 INs

9

The V0 IN populations include a dorsal, inhibitory population (V0D) and ventral, excitatory
population (V0V) and arise near the medial neural tube from Dbx1+ progenitors [54–56]. V0 INs
have mostly ascending, commissural projections to other INs of the ventral laminae, but Pitx2+
subpopulations of V0V INs, including both glutamatergic (V0G) and cholinergic (V0C) INs, have
ipsilateral projections, with V0C INs shown to modulate MN output in the locomotor CPG [57].
Involved in left-right alternation, the glutamatergic V0V INs express Evx1 and contribute their
role in fast locomotion in rodents, while the inhibitory V0D INs are important at slower
locomotor speeds [58], although the opposite has been observed in larval zebrafish [50]. V0 INs
have also been shown to contribute to bilateral coordination of inspiratory effector muscles in
phrenic CPG circuits [59]. Based on the data presented in this dissertation, there now exists a
protocol to derive V0V INs from mESCs, which will support future investigations into their
interactions with other neuronal populations to elucidate CPG circuits and/or potential motor
recovery after SCI.

V1 INs

The ascending, ipsilaterally-projecting inhibitory V1 INs show up in the intermediate neural tube
and express transcription factor En1 [60–62]. They include some of the well-known inhibitory
populations, Renshaw cells and some of the IaINs, which are involved in recurrent and reciprocal
inhibition, respectively, with MNs [63,64]. Recently, four markers for distinct V1 subpopulations
have been identified as FoxP2, Pou6f2, MafA, and Sp8 – a large proportion of Renshaw cells are
included among the V1 MafA+ population [65,66]. V1 INs arise from Pax6+Dbx2+Nkx6.2+
progenitors [54,67] and establish segmental diversity (lumbar versus thoracic) in addition to the
different subpopulations based on Hox gene expression [68]. Using En1 mutant animals,
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investigators have shown that, broadly, V1 INs are involved in the speed of locomotion through
regulating step cycle duration by inactivating spinal neurons involved with slow movements
[69,70]. PSC-derived induction protocols exist to generate V1 INs [49,71], but more work can be
done to obtain specific subpopulations as they are identified. Future studies could isolate the
different subpopulations for complete characterization.

V2 INs

Progenitors in the ventral neural tube expressing Lhx3, Irx3, and Nkx6.1 that arise just dorsal to
the progenitor MN domain give rise to V2 INs [60,72]. The V2 IN subpopulations include the
V2a, V2b, V2c, and V2d INs, which are marked by Chx10, Gata2/3, Sox1, and Shox2,
respectively [72–75]. Glutamatergic V2a and GABAergic/glycinergic V2b INs [76] make up the
bulk of the V2 population and are specified from a common progenitor determined by Notch
signaling [77], with V2a INs arising sans Notch1 and V2b INs coming from Dll4-activated
Notch1 signaling [47]. The caudally-, ipsilaterally-projecting V2a INs are involved in left-right
locomotor coordination [78] and also contribute to the respiratory CPG [79]. V2b INs share in
contributing inhibitory input to flexor-extensor pairing with the V1 INs [80]. V2c INs’ role and
neurotransmitter type have yet to be determined, although a zebrafish V2 population expressing
sox1a and sox1b, called V2s INs, express glycine and have a role in fast response to touchprovoked escape movements [81]. In mice lacking Shox2, locomotor rhythmicity frequency was
reduced, suggesting a role of the ipsilaterally-projecting, excitatory V2d INs in rhythm
generation [75]. V2a INs have been derived from both mouse [82] and human [83] PSCs, thus
enabling their use in SCI studies; in combination with neural progenitor cells (NPCs),
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transplanted V2a INs were found to improve diaphragm output and performance during
respiratory challenge in a cervical contusion model of SCI in rats [84].

V3 INs

Arising at the most ventral area of the neural tube, just dorsal to the floor plate, V3 progenitors
express Nkx2.2 and Ngn3 [85]. The INs comprise a glutamatergic, largely commissural
population that express Sim1 and Uncx [86–88]. Found to be involved in burst robustness and
balanced left-right locomotor output, V3 INs include two functionally and spatially distinct
subpopulations, dorsal V3d and ventral V3v INs, with the ventral population found to synapse
onto contralateral MNs [86,89]. Further characterization has shown V3v has medial and lateral
subpopulations (V3vMed and V3vLat) that project bilaterally, with V3vLat making bidirectional
connections with ipsilateral MNs while V3vMed connect to the V3vLat INs, thus forming a medial
to lateral layered microcircuit [90]. Furthermore, V3 INs arise over a few days during embryonic
development (E9.5-E12.5), but whether they are specified during early-born or late-born
neurogenic waves determines their ability to diversify into particular subpopulations; this
diversification was found to be regulated by Sim1 in early-born but not late-born V3 INs [91].
Investigations with a mouse C2 SCI model showed that V3 INs initiate tail spasms and
contributed to spasm coordination through reciprocal activity and rhythmic oscillations [92].
There is an induction protocol available to generate V3 INs from mESCs [93], although more
work is needed in the field to find subpopulation markers to determine what populations arise in
these inductions to better direct their use in future studies.
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1.4 Pluripotent and Neural Stem Cells as a Source of
Neuronal Populations
Obtaining a large enough number of the neuronal population of interest is both necessary to
overcome the inevitable transplanted cell death [94,95] and difficult because of their relative
scarcity (consider the low numbers of each spinal vIN subpopulation), sensitivity to isolation
methods [96], and the tedious nature of such methods [96–98]. Thus, using a renewable,
pluripotent source of cells to derive vIN populations for study is a practical way to obtain an
unlimited supply of INs. Pluripotent sources include embryonic stem cells (ESCs) and induced
pluripotent stem cells (iPSCs). With proper expansion and maintenance, the pluripotent source
can be essentially immortal [99,100], and they can be directed through appropriate, timed
activation and/or inhibition of different signaling pathways to differentiate them into the cell
population of interest [101]. In the case of ventral spinal neurons, protocols have been developed
to derive MNs [102] and V3 [93], V2a [82], V1 [49], and now V0V INs [103] from mouse
pluripotent sources; MNs [31,104] and V2a INs [83] also have protocols available to derive them
from human PSCs. However, in addition to their practicality, the drawbacks of using pluripotent
cells as a source for transplantable cells should also be considered, especially in terms of their
use in human therapeutics. This section will discuss the sources to derive neuronal populations,
directing differentiation of different locomotion-associated IN populations, and concerns of
using pluripotent cells as a source for neurons in transplant therapies.
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1.4.1 Sources to Derive Neurons

Common sources to derive neurons for transplantation include PSCs as either embryonic or
induced cells, as well as neural stem and/or progenitor cells (NSPCs), which are commonly
harvested from embryonic tissue [105–107], and sometimes first induced from a PSC source
toward the neural lineage before use [108–111] or directly reprogrammed from adult cells
[112,113]. Embryonic stem cells (ESCs) are pluripotent, self-replicating cells that are plucked
from the inner cell mass of the developing embryo at the blastocyst stage that have the potential
to become any of the three germ lineages: endoderm, mesoderm, and ectoderm [114]. This could
be from a sperm-fertilized egg or from somatic cell nuclear transfer (SCNT), where the nucleus
from an adult/somatic cell is transferred into an enucleated ovum before developing into a
blastocyst [115]. Induced pluripotent stem cells (iPSCs) originate from adult cells that have been
exposed to particular reprogramming factors, such as a combination of transcription factors that
alter the epigenomic landscape, to regain pluripotency [116,117]. NSPCs are a multipotent
population committed to the neural lineage that can differentiate into neuronal restricted or glial
restricted progenitor populations and are commonly chosen as a transplanted population due to
their potential to differentiate into the native cell types of the CNS [113]. Fibroblasts are a
common adult cell type used for reprogramming for iPSCs or NSPCs; these are plentiful,
relatively easy to obtain (often from skin), and have been successfully reprogrammed into
neuronal populations by many investigators [118].

The choice of cell source might be determined by several factors such as existing induction
protocols, the intended use of the derived neuron population, and the time to derive the required
cell type, among other considerations. For example, to study disease-associated mutations or
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gene variants in neuronal function, one might choose iPSCs or directly reprogrammed neurons
from patients with such variants [119]. Alternatively, for animal models, obtaining NSPCs from
tissue is a quick way that might provide enough cells for use, or a particular neuronal population
might be derived from a PSC source to obtain a sufficient number for transplantation studies.

1.4.2 Directing Differentiation of Propriospinal IN Populations Involved in
Motor Control
Deriving a particular population of INs from PSCs can be useful to further study them – their
contribution to CPG circuits or their role in disease, for example - or for use in transplantation to
examine their role in recovering motor function. Some of the propriospinal IN populations
known to be involved in motor circuits have been derived from mouse and/or human PSCs,
usually with hPSC protocols requiring about a 3x duration to induce INs. These protocols aim to
recapitulate some of neuronal development, albeit in a more simplified manner, by directing the
PSCs through neuralization to specific cell fates due to manipulation of signaling cues as occurs
during their native generation. This section will cover current protocols used to derive the
different IN populations from PSCs and characterizations of those cells. Although not all existing
protocols in the literature are discussed, those presented below are those that are available and
most akin to the approach used to generate V0V INs for this dissertation work.

dI6 IN induction

Although there is not a protocol to specifically derive dI6 INs, a protocol to derive either dI1/3 or
dI4/6 INs from human PSCs (hPSCs) in about 5 weeks was recently published [53]. After 6 days,
in a base medium of IMDM with N2 supplement and B-27 supplement (both of which contain
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various factors that support neuronal growth) without Vitamin A (which is metabolized into
retinoic acid [RA]), hPSCs gave rise to Pax6+Sox1+ neuroectoderm cells in these cultures, which
were then allowed to form embryoid bodies (EBs) for 4 days in the presence of RA (1 µM) for
caudalization and Rho kinase (ROCK) inhibitor (10 µM) which reduces apoptosis and improves
EB formation. For a further 7 days, cultures were directed toward a dI1/dI3 fate or dI4/dI6 fate
using 1 µM RA and 10 ng/ml BMP4 (for dorsal IN subtype specification) or 1 µM RA only,
respectively. For the subsequent 19 days, cultures were differentiated in Neurobasal medium
with N2 supplement and B-27 supplement containing RA/BMP4 (dI1/3) or RA (dI4/6) and
matured in a DMEM/F-12 base medium with N2 supplement, B-27 supplement, and Vitamin C
(a.k.a. Ascorbic Acid [AA]) which “enhances the differentiation process” containing RA/BMP4
(dI1/3) or RA (dI4/6) until day 36. These protocols yielded either 10%–20% of the culture as
LHX2+ dI1s and Isl1+TLX3+ dI3 INs or 30%–40% of the culture as LHX1/5+PAX2+ dI4/dI6 INs.
The investigators did not report any expression of synaptic or mature neuronal markers beyond
pan-neuronal marker βIII tubulin, nor any data regarding electrophysiological activity, which is
difficult to perform in mixed neuronal cultures.

V0 IN induction

Now there is a protocol to derive V0V INs from PSCs (see chapter 2 for the induction protocol to
derive V0V INs from mESCs generated during my graduate work), but there are no protocols to
specifically induce other V0 IN subpopulations. However, in investigations examining retinoids
on neural induction, previous studies showed exposing mESCs to RA could generate GAD+
neurons [120] and Evx1+/Lim1+ neurons [121] by first forming EBs for 4 days (known as 4-),
followed by exposure to 500 nM RA for 4 days (known as 4+) and at least 2 days of further
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culture on laminin. From the Bain et al. 1995 study, it seems likely that the GAD+ cells include
some dorsal spinal IN populations such as dI4/dI6 INs as well as V0D INs, which are known to
be inhibitory, as the protocol has some similarities to the recent dI4/6 IN protocol (although on a
different time scale and with no components necessary for human cells) as well as to our
protocol to generate cells expressing mRNA and/or protein of the V0 IN progenitor (p0)
transcription factor marker Dbx1 and IN marker Evx1 using 4-/4+ induction with 1 µM RA.
Furthermore, they did not see expression of BF-1, an anterior CNS marker, suggesting RA
induction generated more caudal, spinal neurons. The Huettner lab’s examination of retinoids on
neural induction expanded on that study, as it used the same basic protocol and showed they
produced around 18% of neurons expressing dI4/dI6 IN markers and just over 20% of neurons
expressing Evx1 and Lim1, markers for V0V INs.

V1 IN induction

Using a fluorescent reporter, lineage traceable mESC line, Hoang et al. generated V1 INs using a
2-/6+ protocol with 2 days of EB formation followed by 6 days with exposure to 5 nM
smoothened agonist (SAG), to activate Shh signaling, and 1 µM RA for caudalization in a base
medium of 1:1 ratio of DMEM-F12 and Neurobasal medium [49]. Examining the cultures at day
8 showed about 39% of the cultured cells were fluorescent, thus expressed En1. By increasing
the RA concentration, they were able to increase the proportion of calbindin-expressing Renshaw
cells, one of the MafA+ V1 IN subtypes. By inhibiting Notch signaling from day 4 to 5, Foxp2+
cells were eliminated in favor of producing MafA+ cells. They characterized mESC-derived,
fluorescence-activated cell sorting (FACS)-isolated V1 INs transplanted in chick embryos and
observed expected migration and axon extension of Renshaw cells, although electrophysiological
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characterization showed their burst-tonic behavior was not different from other V1 INs,
signifying they were still immature at the time of measurement. They also observed the
occurrence of synapse formation of Renshaw cells to and from MNs in co-cultures, which is
favorable for these cells to influence motor circuits.

V2 IN induction

V2a INs have been induced using both mouse and human PSCs [82,83,122], but no other V2 IN
subpopulations currently have published induction protocols. V2a INs were induced after 6 days
using mESCs; cells formed EBs for 2 days in DFK5 - a base medium of DMEM-F12 with
knockout serum replacement (KSR) - followed by 2 days in DFK5 with 10 nM RA for
caudalization and 1 μM purmorphamine (purm), a smoothened agonist, to activate Shh signaling.
From days 4 to 6, EBs were grown in DFK5 with 10 nM RA, 1 μM purm, and 5 μM N-[N-(3,5difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), a γ-secretase inhibitor, to
inhibit Notch signaling. V2a INs were induced after 17 days using hPSCs; cells formed EBs in
mTeSR (a defined medium for hPSCs maintenance) containing ROCK inhibitor, and TGF-β and
BMP inhibitors for dual SMAD inhibition, which has been shown to promote rapid, efficient
neuralization [123]. After 5 days of EB formation, cultures are grown in a base medium of
DMEM-F12 with N2 supplement containing AA, TGF-β and BMP inhibitors, brain-derived
neurotrophic factor (BDNF) – a neurotrophic factor known to differentiate NPCs to neurons
[124] - and 100 nM RA for caudalization. From days 7 to 17, EBs are grown in the same
conditions as on day 5 but also with 100 nM purm and 1 μM DAPT. At the end of induction,
these protocols yield approximately 20% (mESC) and 40% (hPSC) of the cells expressing the
V2a IN marker Chx10. Some electrophysiological and maturation characterizations were
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completed with the PSC-derived V2a INs. The mESC-derived V2a INs show maturation over
time through expression of neurotransmitter receptors, expression of the glutamatergic cell
marker VGLUT2, and cell membrane properties (as measured by whole-cell patch clamp
electrophysiology) comparable to native V2a INs that were examined in slice cultures or spinal
cord preparations [125]. V2a INs from hPSCs were transplanted into mice and showed
expression of VGLUT2 and integration with host tissue [83].

V3 IN induction

The most ventral IN subtype, V3 INs, has been derived from mESCs but not hPSCs, and
subtypes have not been clearly identified since they have been defined spatiotemporally rather
than by protein markers [93]. In DFK5 medium, 2 days of EB formation followed by 6 days of
exposure to 10 nM RA and 500 nM SAG yielded approximately 10-20% of cells expressing V3
IN markers such as Sim1 and Nkx2.2 [93,126]. V3 INs showed maturation over time as mRNA
expression of synaptic markers increased drastically, as well as by expression of neurotransmitter
receptors and synaptic protein markers including VGLUT2. Electrophysiological examination
showed an increase in neurons that only fired single action potentials over time; however, those
that fired multiple action potentials had characteristics comparable to V3v IN slice recordings.

1.4.3 Concerns and Limitations of Using PSCs as a Source

Although PSCs are a reasonable option to obtain a renewable, scalable supply of the neuronal
population of choice, there are several limitations that should be considered. In terms of concerns
for therapeutic relevance, transplanted cells could trigger an immune response, lead to teratoma
formation, or if they have genetic modifications, gene expression may not be temporally
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controlled to affect any lasting benefit. There are also ethical concerns with using PSCs that are
not currently relevant to our work but may become relevant in future studies.

PSCs have become popular in therapeutic, translational investigations and in clinical trials
because of their advantages; however, the therapeutic benefits must outweigh the risks associated
with receiving cell populations derived from multipotent sources, or those risks must be
addressed and overcome. Autologous PSCs, which have been derived from the host to which
they will be transplanted, are ideal in terms of immunogenicity, but any transplanted cells, even
autologous ones, must be examined for possible immune responses [115,127]. Moreover, studies
have shown that although PSCs may be immune-privileged, their differentiated progeny could
acquire the molecules that trigger immune responses, the major histocompatibility complexes
[115]. Some recent work has been done to address this, for example, by creating humanized mice
to investigate hPSC immunogenicity [128].

Another potential concern with PSC-derived cell therapies is whether any genetic modifications
have been made to the cells. Prospective dangers associated with the method of genetic alteration
(i.e. lentivirus) should be considered before the cells go back into the patient (for further
discussion, see section 1.5.2 Genetic Manipulation of Target Cells). Also, genetic modifications
of transplanted cells may express a gene for therapeutic benefit for a particular period of time,
but if that period is too short, no benefit may be achieved, and if too long, chronic expression of
a gene may eventually lead to other morbidities or undesirable, secondary effects. Although the
following example is in peripheral nerve tissue using adult cell types, it illustrates this point well:
some recent work from our lab and others’ examined the “candy-store” effect, where
overexpression of glial cell line-derived neurotrophic factor (GDNF) by Schwann cells promotes
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axonal extension toward high GDNF concentrations after peripheral nerve injury, but when the
Schwann cells constitutively express high levels of GDNF, axons become trapped and form
dense coils that cannot continue the course to desired end targets [129,130]. The trapping effect
was overcome when GDNF expression was spatiotemporally controlled, thus rendering the
therapeutic effort more successful [131]. There have also been investigations into epigenetic
memory of iPSCs and whether such memory could be counterproductive for treatment, as they
are more likely to differentiate toward the adult lineage from which they were initially derived
[115].

An additional, probable drawback of using neuronal cells derived from PSCs is that induction
protocols cannot achieve 100% efficient differentiation toward the lineage of choice, often with
PSCs or multipotent cell types remaining in cultures; transplanting any remaining PSCs can lead
to formation of teratomas (non-cancerous tumors made of a mixture of many cell types of the
three germ lineages). There has been some work to remove PSCs from their derived NSPC
populations [132], and some tools from our lab, including some of my thesis work, include
selectable mESC lines to allow for removal of PSCs and purification of the neuronal target
population [125,126,133,134].

There are ethical concerns with using PSCs, especially human embryonic stem cells (hESCs),
but one can refer to the guidelines set by the International Society for Stem Cell Research
(ISSCR) for details on current proposed regulations and oversight on the use of PSCs in research
and translational medicine [135]. Research in our laboratory does not require oversight since we
do not currently use human cells; if future investigations were to use human cells, their use in
vitro or in postnatal animal models – such as transplantation of neurons derived from iPSCs in a
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rodent SCI model – would still be exempt from special overview. Once research requires
derivation of hESC lines from embryonic tissue or performs genetic alterations in human
embryos, oversight of the investigation is suggested, but such research is not currently of interest
in our lab. Further studies are necessary to address the roll of propriospinal INs in CPG circuits
and their potential for motor recovery in animal models before transitioning to using human
cells.

1.5 Genetic Manipulation of Target Cells
Genetic modifications can alter a cell line to improve its use as a tool in investigations, provide a
therapeutic agent released from transplanted cells, or even correct an underlying cause of
disease. Before genetic manipulations are performed, several considerations should be
addressed, such as the “why”, “how”, “when” (and/or maybe, “how long”), and “where” of the
genetic alteration and its effects. This section will discuss why genetic manipulations are useful
in research and therapies, different methods of making gene alterations, and how these
genetically modified cells can be used in the lab and the clinic.

1.5.1 Purposes of Genetic Manipulation

Genetic manipulation of a cell population can enhance its use as a research tool or as a
therapeutic agent in the patients. It can allow for identification or isolation of a particular cell
type, controlled de/activation of proteins to change neuronal activity or observation of such
changes, and changes in protein expression to alter the neuron or its environment. The examples
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given in this section are not exhaustive, but they are relevant to investigations that could make
use of propriospinal INs both in vitro and in vivo.

Isolating/identifying specific neuronal populations

Isolating a particular neuronal population – whether physically or visually - can be useful to
characterize its development and gene expression profile, determine its activity, and to examine
its contribution to motor function or recovery. For example, one issue with deriving neuronal
populations from PSCs, as mentioned above, is that the heterogenous induction culture would
still contain other, undesirable cell types. Determining the activity of the population of interest
would thus be difficult in such a mixed, uncontrolled environment. A method to overcome this
problem is to use lineage-specific gene expression to enable isolation of the population of
interest. This could be accomplished through various approaches, a common choice being
expression of a visibly detectable protein such as fluorescent or enzyme reporters like green
fluorescent protein (GFP) or β-galactosidase, respectively. With fluorescent protein expression,
FACS is now often used to separate the fluorescent cells of choice from their source (though
shear forces during sorting is detrimental to neurons, leading to inefficient isolation
[96,136,137]); however, downstream applications of FACs-isolated neurons are usually gene or
protein analyses rather than to maintain living cells. Reporter proteins additionally facilitate
lineage tracing, which would allow investigators to identify and examine particular cell types in
vivo or in explants. Investigators can make use of reporter mouse lines, which have
recombination sites flanking stop codons in series with reporter protein gene expression, and a
mouse line with a cell-specific gene driving recombinase expression. Some efficient in vivo
recombination systems include Cre recombinase with loxP sites, codon-optimized flippase
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(FLPo) with FRT sites, and codon-optimized phiC31 integrase (ΦC31o) with attB/attP sites
[138]. More recently discovered systems include Vika/vox and Dre/rox systems [139]. Once the
mice strains are crossed, since recombinase expression is isolated to the specific cell population,
it recombines the stop codon out of the sequence so only those cells express the reporter, thus
tracing that lineage. Another method to isolate a particular neuronal population is to use cellspecific expression of an antibiotic resistance gene and then select the desired neurons with the
associated antibiotic. Our lab has used the gene regulatory elements of a neuronal populationspecific transcription factor marker, such as Olig2 [133], Hb9 [134], Sim1 [126], Chx10 [125],
and Evx1 (this work), to drive expression of an enzyme that confers resistance to puromycin
antibiotic – puromycin N-acetyltransferase (PAC) – which allows selection of our intended,
specific neuronal populations from mESC cultures.

Controlling and measuring neuronal activity

There has been a considerable number of studies recently that make use of gene modifications to
create neural sensors and effectors. This includes using genetically modified organisms and cell
lines to introduce optogenetic, thermogenetic, and chemogenetic receptors, and calcium, pH,
voltage, or neurotransmitter sensors. The effectors are used to activate or inactivate the specific
neuronal population that contains genetically modified channels that alter neuronal membrane
properties upon application of a particular stimulus. The sensors are used to detect neuronal
activity.

Optogenetic tools make use of opsins, which are G-protein coupled receptors (GPCRs) that allow
flow of particular ions across the membrane upon exposure to light [140]. Halorhodopsins drive
chloride inward in response to yellow light, while yellow or green light causes archeorhodopsins
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to drive protons out of the cell; these opsins hyperpolarize the membrane to inactivate neurons.
As non-specific cation pumps affecting membrane depolarization, channelrhodopsins (ChR) are
used to activate neurons, such as through application of blue light to ChR2.

Thermogenetic tools also activate or inactivate neurons through membrane channels but in
response to temperature changes. Because of some of the challenges of using thermosensitive
channels, such as the physiological sensitivity of different organisms to temperature fluctuations,
thermogenetics have been most widely used in fruit flies [140]. For inhibition, a modified
Dynamin GTPase inhibits endocytosis, preventing uptake of neurotransmitters at the synapse to
inactivate neuronal responses above 29°C. A family of channels, Transient Receptor Potentials
(TRPs), can respond to 1-2°C changes to activate neurons by conducting cations.

Chemogenetic tools can either be used for neuronal activation or inactivation after binding
particular ligands and depending on which receptor is expressed. Designer receptors exclusively
activated by designer drugs (DREADD) are modified GPCRs often found in neurons that are
only responsive to a few ligands, such as clozapine-N-oxide, and alter neuronal excitability by
hyperpolarizing or depolarizing the membrane potential depending on which G protein is
coupled with the receptor [141,142]. Gs coupling activates adenylyl cyclase and Gq coupling
activates phospholipase C, both resulting in neuronal activation. Neuronal inhibition can be
achieved by Gi coupling through reduction of intracellular cAMP.

Biosensors can help determine the functionality of any isolated neuronal population, whether
they are used in vitro or in vivo, as their activity will affect the circuitry to which they become
integrated. This may be especially important for PSC-derived neurons since they are not the bona
fide population. Therefore, use of various biosensors, including indicators of calcium, voltage,
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release of neurotransmitters, or pH, can give investigators different measurements for neural
characterizations. Although there may be synthetic small molecule alternatives to genetically
altering the cells to incorporate the sensors, chemical application is short-lived and potentially
expensive depending on the required duration of its use. Generally, it seems small molecule
application is more practical for in vitro use while genetic modification is more suited for in vivo
studies. There are many factors for users choosing a biosensor, such as detection method (i.e.
what sort of microscopy can detect a particular sensor), kinetics of the sensor output (i.e.
consider whether a calcium indicator can show bursting action potentials), the spatial resolution
(i.e. can you detect changes at a synapse, in axons, or whole cell), how well the sensor output
represents the neural output (i.e. is the absolute membrane potential represented by a voltage
indicator) and others [143–146]. Also, a general challenge for using biosensors is the tissue depth
of the neurons being studied, with deeper structures suffering from greater refraction and thus
more difficulty in achieving good signal to noise ratios during detection.

Changing protein expression

Gene expression can be changed to exogenously express, overexpress, knockout, or mutate
(whether for correction or introduction) the encoded protein to alter cell functions or their ability
to interact with their surroundings. The previous subsections discussed different uses of knockin
of genes for exogenous expression of proteins to aid in identifying, controlling, and measuring
neurons and their activity. Changing gene expression, whether by overexpression or knockout,
can help determine the contribution of particular proteins to disease states or their amelioration,
growth support, roles in development, or normal neuronal activity, for example. However, one
must consider that such drastic change of gene expression could be accompanied with
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obfuscating effects, such as downstream proteins also being affected in overexpression or other
proteins compensating for lost function in knockouts. Mutating genes can shed light on the role
of a particular protein or what protein domains are involved in both normal and diseaseassociated neuronal functions.

1.5.2 Methods of Genetic Manipulation

To genetically modify cells, one must consider how to facilitate the genetic change, including
what gene-editing tool to use and how to introduce it and any associated genetic material to the
cell. Investigators often use engineered/programmable nucleases or viral methods to introduce
the genetic material to the cell. There are also non-viral delivery methods such as nanoparticles
or methods of physically creating an opening, such as pores by electroporation or ultrasoundbased disruption.

Nuclease-based editing

Programmable nucleases are now often used as a gene editing tools as they have been engineered
for targeted editing. One can create a double-stranded break (DSB) at a targeted location in a
gene locus, which can be used for homology-directed repair (HDR)-based insertion of a gene or
point mutation when donor DNA containing homologous sequences is also introduced, or to
disrupt the genetic sequence and its expression by non-homologous end joining (NHEJ), which
can delete or insert random nucleotides. Such nuclease tools include zinc-finger nucleases
(ZFN), transcription activator-like effector nucleases (TALEN), and the current, more widely
used clustered regulatory interspaced short palindromic repeats (CRISPR) with the nuclease
CRISPR-associated protein 9 (Cas9) (CRISPR/Cas9) [147,148]. However, for post-mitotic cells
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such as neurons, using a DSB for HDR is not feasible, since HDR is cell cycle dependent; as
neurons are no longer proliferative, the cell’s DNA repair machinery that is necessary to correct
the DSB by HDR is not active. One study elucidated part of the mechanism involved in HDR
suppression, which they showed could be applied to non-proliferative cells using CRISPR/Cas9
[149], but so far this has not been applied to neurons to enable HDR for gene editing. Instead, in
adult tissues, nucleases are applied to the CNS to edit other, proliferative cell types to affect the
intended modification [150], or nucleases can be applied to PSCs or NPSCs to enable HDR
before cells have differentiated to post-mitotic subtypes [147,151,152]. Also, exposure to Cas9
can lead to adaptive immunity in some patients, a potential issue for translation of its use in
human genome editing, but further studies are needed to determine the extent and implications of
this problem [153].

Viral gene delivery

To directly modify neurons, viral methods are the usual go-to for investigators since they can
transduce both proliferative and nondividing cells. Lentivirus (LV), adenovirus (AV), and adenoassociated virus (AAV) are used to introduce the genetic material into the target cell, with LV
integrating the genetic modification into the host cell’s DNA, while AV and AAV generally do
not [154]. LV can be used for longer, more stable gene expression due to its ability to integrate
the material into DNA; however for translational purposes, integration is a potential concern, as
it can cause insertional mutagenesis [154,155]. AVs are preferred for delivery of large genetic
payloads and transient expression, and, although they were shown to generate immunogenicity
and inflammation [154], their safety has improved such that they are currently the most utilized
viral tool for gene therapy clinical trials [155]. AAVs are small vectors that are relatively easy to
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modify for a specific use, but recent studies suggest that they may opportunistically integrate into
host cell DNA, which is a safety concern for use in the clinic [155].

The components of the viral tool will affect the efficiency and type of cell that are transduced;
this includes the packaging proteins used to envelop the genetic payload and the gene regulatory
elements such as enhancers, promotors, etcetera [155]. Neurons can be preferentially transduced
by using appropriate serotypes or pseudotyping of the viral packaging in addition to the route of
viral administration. For example, for LV, the HIV-based vector can be pseudotyped with
packaging using VSV-G, which is a glycoprotein from another non-pathogenic virus – vesicular
stomatitis virus (VSV) - that allows it to transduce neurons (or has neuronal tropism) [154]. For
AAVs, there are several serotypes that target neurons, but one group made a chimera of AAV2,
which has the greatest neuronal tropism, and AAV9, which has the most efficient CNS
transduction, to achieve improved, widespread neuronal transduction when it was introduced
intrathecally to the cerebrospinal fluid [150]. This group also used the human synapsin (hSyn)
promotor, although this is a relatively weak promotor, to achieve neuronal specificity; another
common stronger, mammalian-based promotor is cytomegalovirus (CMV), although it is not
neuron-specific [154]. Therefore, depending on the desired target population, these factors must
be weighed and properly combined for the best outcomes.

Non-viral gene delivery

Non-viral methods are attractive in terms of safety but have relatively less efficient transfection
of genetic material into cells. For highly proliferative cells such as PSCs and NSPCs, low
efficiency is not a major concern, as successfully modified clones can be screened and expanded.
In vivo non-viral gene delivery has several hurdles to overcome, such as interactions with the
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extracellular environment, including maintaining stability and extravasation through blood
vessels (requiring that the delivery method is able to penetrate the blood-brain barrier in the
CNS), cellular internalization and escaping lysosomal degradation, and actually traversing the
cell to the nucleus for expression [156]. There are both physical and chemical methods of gene
delivery.

Physical methods of introducing genetic material are simple, cheap, and practical, especially for
in vitro studies, while some in vivo techniques may require surgical access to the tissue.
Electroporation allows entry of exogenous material, such as plasmid DNA, to cells by creating
pores in the cell membrane after application of a high voltage pulse. Sonoporation also creates
membrane pores through microbubble cavitation by applying ultrasound waves. Using magnetic
nanoparticles complexed with the genetic material, magnetofection allows delivery during
exposure to a magnetic field. There are other methods of non-viral delivery, such as gene gun,
hydrodynamic injection, microneedle, etc., but these are not currently relevant for use in CNS.

There are also chemical methods of transfecting cells, such as using cationic lipids, cationic
polymers, gemini surfactants, dendrimer macromolecules, polypeptide vectors, and
nanoparticles. These materials contain features to both interact with the cell and with the
negatively charged DNA. Cationic lipids and gemini surfactants are amphiphilic materials with
hydrophilic cationic regions associating with DNA while hydrophobic regions associate with the
cell membrane. Cationic polymers and dendrimers are water soluble materials that condense
DNA and protect it from enzymatic degradation. With cell-penetrating peptides to introduce
DNA to the cell, polypeptide vectors form electrostatic complexes with the genetic material.
Nanoparticles can be tuned to enhance particular features, such as biodegradability or
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biocompatibility, but are often made of inert materials that must be functionalized to interact
with the cell and DNA.

Investigators have many possible methods available to them to introduce genetic changes to the
desired cell population. There are also studies ongoing to improve these tools. Depending on the
target cell, the intended genetic change, the preferred efficiency, or the degree of safety required,
different types of delivery vectors should be considered.

1.5.3 Examples of Uses for Genetically Manipulated Neuronal Populations

Isolated neurons, especially those that have been modified to express fluorescent proteins, are
probably one of the most commonly used tools for neuroscientists. Lineage tracing has been used
to determine the development of ventral IN populations [157], the identification and function of
subpopulations of some INs [57], and even their role in reforming connections and motor
recovery after SCI [78]. Many investigators have taken advantage of effectors to examine
neuronal activity. Using optogenetic activation and suppression of V2b IN activity helped reveal
their role in speed control in larval zebrafish [158]. It is also possible to combine expression of a
visible protein, such as GFP, and an antibiotic selective marker, such as PAC, by introducing the
fluorescent protein gene into a safe harbor locus (Rosa26 often is used) and the selective gene
into a cell-specific gene locus. This allows isolation of a PSC-derived neuronal population that
can then be transplanted and imaged to easily locate them, allowing discernment of their
integration and interaction with host tissue [84,159]. Isolated neurons can also be used in studies
to determine their contribution to networks or to improve our interpretation of results from such
studies; for example, V2a INs derived from a selectable mESC line were used in MEAs to
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develop a connectivity assay by measuring the correlative activity among the cultured neurons
[160].

Editing cells to monitor or modify their activity can help researchers determine their contribution
to circuits, such as by activating effectors and observing coinciding network changes. Although
there are many publications available, one group generated several effector and sensor tools
including mouse lines (many of which they contributed to Jackson Labs) and AAV vectors so
that more controlled, intersectional approaches could be used to better target more defined
neuronal populations. For example, they created various mouse lines using the tetracycline
response element (TRE) in the TIGRE locus, which they showed generated more robust reporter
expression than using the common CAG promoter-driven expression in the Rosa26 locus. For a
voltage sensor mouse, they used TIGRE-TRE-LoxP-stop-LoxP-VSFP-Butterfly 1.2 (a voltage
indicator) crossed with a Rasgrf2-dCre (which they claim is preferentially expressed in cortical
layer II/III neurons) mouse and a Camk2a- tetracycline transactivator (tTA, also known as TetOff; they claim this mouse has expression in forebrain excitatory neurons and striatal medium
spiny neurons). This controlled genetic crossing allowed them to record evoked responses only
in excitatory cortical layer II/III neurons specific to brain regions of their associated stimuli such
as visual, auditory, and sensory.

By changing protein expression, investigators can determine its importance based on associated
changes in neuronal function. For example, KLF7 is involved in neuroectodermal specification
and axonal outgrowth after optic nerve injury; its overexpression in vitro increased neurite
outgrowth and in a mouse SCI model promoted axonal plasticity and myelination as well as
improving motor function [161]. Other groups overexpressed Mash-1 [162] or Wnt5a [163] in
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transplanted neural stem cells (NSCs) to enhance neural differentiation, which improved motor
function recovery after SCI. After determining that α-synuclein expression increased after SCI,
investigators used a knockout mouse to show that it is necessary for hindlimb function mediated
by dopaminergic neurons, even though removing it improved the inflammatory response and
sparing of neurons [164]. Another group examined SARM1, which is autoinhibited in healthy
neurons to prevent axon degeneration, and mutations in different protein domains showed which
of them are involved in autoinhibition, providing a therapeutic target for prevention of axon
degeneration after injury [165].

1.6 Summary
The work in our laboratory is inspired by neurological diseases and injuries, especially SCI.
Considering methods to improve motor recovery after SCI, combinatorial approaches seem most
likely to succeed, as they address several aspects of axonal recovery, including removing axonal
growth-inhibitory factors from the injury site, supporting axonal growth by release of
neurotrophic factors and incorporation of growth-supportive extracellular matrix, and providing
transplanted cells to contribute additional axonal connections. Transplanted cells must be
obtained from either living hosts and/or from differentiating PSC sources, which would require
an appropriate differentiation protocol to derive the desired population.

Neuronal populations to consider for transplantation include those that have shown axonal
sprouting that has contributed to motor recovery, such as the propriospinal ventral INs. To obtain
a scalable source of such INs for transplantation, they can be derived from PSCs, Mouse ESCs
have several induction protocols available to derive different IN populations, and these protocols
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result in post-mitotic neurons, which show maturation over time, on a shorter timeframe than do
human PSCs, enabling faster turnaround of experimental results. However, PSC-derived IN
cultures are heterogenous and can possibly include remnant PSCs, which are teratoma-forming if
transplanted and which can result in overcrowded in vitro cultures. This requires a method of
purifying the IN population of interest for improved use both in vitro and in vivo. To isolate INs
derived from mESC cultures, we have created transgenic mESC lines that use cell-type specific
gene regulatory elements to drive expression of an antibiotic-based selective gene, PAC. To
achieve this, we have recently used CRISPR-Cas9 mediated HDR to integrate PAC into a single
locus of a population-specific gene.

The work presented in this document is focused on the development of a differentiation protocol
to derive one of the vIN populations, V0V INs, as well as generating a mESC transgenic line to
allow for purifying V0V INs from the culture. For the induction protocol, IN development and
other IN induction protocols were taken into consideration to find the most efficient method. To
purify the induced V0V INs, PAC was inserted into the Evx1 locus, as Evx1 is a distinguishing
marker for V0V INs. Confirmation of PAC insertion, neuronal culture selection, and neuronal
activity was completed to ensure a useable transgenic tool was produced.
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Chapter 2: Induction of Ventral Spinal V0
Interneurons from Mouse Embryonic Stem
Cells
2.1 Abstract
The ventral spinal population of V0 interneurons (INs) contribute to the coordinated movements
directed by spinal central pattern generators (CPGs), including respiratory circuits and left-right
alternation in locomotion. One challenge in studying V0 INs has been the limited number of cells
that can be isolated from primary sources for basic research or therapeutic use. However,
derivation from a pluripotent source, such as has been done recently for other IN populations,
could resolve this issue. However, there is currently no protocol to specifically derive V0
interneurons from pluripotent cell types. To generate an induction protocol, mouse embryonic
stem cells (mESCs) were grown in suspension culture and then exposed to retinoic acid (RA)
and collected at different time points to measure mRNA expression of the V0 progenitor
transcription factor marker, Dbx1, and post-mitotic transcription factor marker, Evx1. The
cultures were also exposed to the sonic hedgehog signaling pathway agonist purmorphamine
(purm) and the Notch signaling pathway inhibitor N-{N-(3,5-difluorophenacetyl-L-alanyl)}-(S)phenylglycine-t-butyl-ester (DAPT) to determine if either of these pathways contribute to V0 IN
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induction, specifically the ventral (V0V) subpopulation. From the various parameters tested, the
final protocol that generated the greatest percentage of cells expressing V0V IN markers was an 8
day protocol using 4 days of suspension culture to form embryoid bodies followed by addition of
1 µM RA from days 4 to 8, 100 nM purm from days 4 to 6, and 5 µM DAPT from days 6 to 8.
This protocol will allow investigators to obtain V0 IN cultures for use in in vitro studies, such as
those examining CPG microcircuits, electrophysiological characterization, or even for
transplantation studies in injury or disease models.

2.2 Introduction
Spinal interneurons (INs) generate a complex relay between the body and the brain, as dorsal IN
types confer sensory information while ventral IN types have roles in motor output. The ventral
IN circuits formed through various interconnections with each other, motor neurons (MNs), and
the dorsal INs allow for the rhythmic, oscillatory movements – walking, breathing, swimming,
etc. – that are generated from circuits centralized in the spinal cord, central pattern generators
(CPGs) [42,166]. These movements occur as neural circuits of the CPG excite or inhibit the
appropriate muscle groups to create coordinated motions. Ventral INs thus must project axons in
many directions along the rostro-caudal axis and relative to the midline, with commissurallyprojecting INs involved in left-right coordination to allow for alternation or synchronous motion
[166–168].

V0 INs include a large proportion of cells having commissural axonal projections and are known
to contribute to left-right alternation [58,169]. V0 IN progenitors (p0s) arise near the centralmost ventral neural tube, adjacent to the dorsal progenitor domains, near the central canal and
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express the transcription factor Dbx1 (Figure 2.1) [54]. These p0 progenitors mature into two
major subclasses, ventral V0V and dorsal V0D INs, with the excitatory V0V INs distinguished by
transient expression of the transcription factor Evx1, while the inhibitory V0D INs as yet have no
specific, direct marker for their identification (Figure 2.1B) [55,56,169]. V0V INs are further
diversified into the uncommon, ipsilaterally-projecting Pitx2+ subclasses V0G (glutamatergic)
and V0C (cholinergic), which form monosynaptic connections with MNs [170].

Figure 2.1: Schematic of RA and Shh gradient specifying IN progenitor domains and
current distinctive markers of V0 IN subpopulations
(A) Release of retinoic acid (RA) from the adjacent somitic mesoderm (SM) specifies the
spinal neural identity of the developing neural tube. Sonic hedgehog (Shh) released from the
notochord (NC) and ventral (V) floor plate (FP) forms a concentration gradient; this gradient
determines the different ventral interneuron progenitor domains for p3, pMN, p2, p1, and p0
which respectively become the V3 INs, MNs, V2 INs, V1 INs, and V0 INs; only the dI6
progenitor domain, pd6, is shown of the dorsal domains. (B) The V0 progenitors, p0, are
identified by Dbx1 transcription factor expression and give rise to the post-mitotic V0 IN
population. V0 INs have been defined by subpopulations of dorsal V0D, which currently have
no distinct markers, and the ventral V0V identified by expression of transcription factors Evx1
and Lim1. V0V INs are further divided into the Pitx2-expressing glutamatergic V0G and
cholinergic V0C populations.
Genetic ablation studies in mice showed that the two major subclasses are recruited in a
frequency-dependent manner during locomotion; the inhibitory V0D INs are more active at low
speeds and the excitatory V0V interneurons at higher frequencies [58]. However, a recent study
in larval zebrafish showed that, in contrast to mice, V0D INs are important at higher frequencies
[50]. V0 INs also have been shown to contribute to backward locomotion and scratching –
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rhythmic movements - and postural correction and righting behavior - non-rhythmic motor
functions [171]. Much remains to fully understand and characterize V0 IN subtypes and their
role in motor circuits including the locomotor CPG.

To better study V0 IN populations and their contributions to CPGs, a means of obtaining a large
number of V0 INs would be beneficial. Deriving INs from a pluripotent cell type, such as
induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs), is a means of isolating a
potentially large number of INs from an expandable source. Recently, groups have used human
PSCs and mouse ESCs (mESCs) to generate different ventral IN populations including V1, V2a,
and V3, as well as motor neurons (MNs) [31,49,82,83,93,102,123,172]. These differentiation
protocols yield post-mitotic neurons expressing population-specific markers in mouse cells after
~7 days and in human cells after ~21 days. After induction, examination of expression and
localization of mature markers, such as synaptic and dendritic proteins, as well as
electrophysiological properties of the generated neurons shows that PSC-derived mouse neurons
mature over ~ 2 to 4 weeks while human neurons take ~ 5 to 9 weeks to mature [31,83,125,126].
The work presented in this article uses methods similar to those previously shown to be
successful in deriving ventral mouse INs and MNs to generate post-mitotic V0V INs from
mESCs in about a week and maturation continues over the next 2 weeks post-induction. These
mouse neurons are a useful tool in comparative investigations for which a human PSC-derived
neurons are available, such as with the V2a INs or MNs but they allow studies to be performed
on a shorter time scale - for example, in co-cultures to examine how different combinations of
INs and MNs change network dynamics in vitro [71,173].
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Approaches deriving INs and MNs from pluripotent sources recapitulate some aspects of normal
spinal cord development. During this complex process, the ventral neural tube is exposed to
retinoic acid (RA) from the adjacent somitic mesoderm and a gradient of sonic hedgehog (Shh)
from a ventral source – beginning from the notochord and later including the floorplate (see
Figure 2.1A). RA caudalizes the tissue, allowing for spinal identity versus midbrain or cortical
identities, whereas the Shh gradient establishes the boundaries of the different ventral IN
progenitor domains. The progenitor and post-mitotic IN domains can be identified by particular
transcription factor profiles, with progenitor V0 INs (p0s) expressing the homeobox protein
Dbx1 [54], and a post-mitotic, ventral subpopulation – V0V INs – expressing the homeobox
protein Evx1 (Figure 2.1A) [55,56,169]. Lim1 is another transcription factor expressed in several
ventral IN populations and distinguishes V0V INs from a dorsal IN population, dI1, which
transiently expresses Evx1 but does not express Lim1 [54]. Therefore, in this study, Dbx1 and
Evx1 with Lim1 are used as markers of p0s and V0V INs, respectively, in induced cultures
derived from mESCs.

Using PSCs to induce any cell type will result in a heterogenous culture, likely including
populations that arise close to the induced population during development. For V0 INs, the
neighboring populations include dI6, the adjacent dorsal population that expresses Dmrt3, and
the adjacent ventral V1 INs, which express En1 (Figure 2.1A) [38,174,175]. V2a INs transiently
express the transcription factor Chx10 (Figure 2.1A) and can be induced from PSCs
preferentially over the V2b IN subtype through Notch inhibition [47,82,83]. Olig2 marks
progenitor MNs (pMNs) before oligodendrogliogenesis, soon after which it can be considered a
glial marker, and post-mitotic MNs express Hb9 [176,177].

39

An induction protocol to generate INs from mESCs should ideally produce a considerable
proportion of INs among the heterogenous resultant mixture, yet practically, it should entail as
simple and quick a procedure as possible. Existing protocols used to derive various spinal
neurons can be informative for possible methods to derive V0 INs from mESCs. To induce
mESCs to form MNs and V2a INs, cells are cultured in suspension for 2 days in the absence of
any morphogens (2-) and allowed to form embryoid bodies (EBs) to simulate embryogenesis.
EBs are exposed to RA and a Shh agonist (purmorphamine [purm] for V2a and smoothened
agonist [SAG] for MNs) are added to the EBs for another 4 days (4+) [82,102]. V2a IN induction
also includes exposure to a Notch signaling inhibitor during the last 2 days to preferentially
specify the V2a over V2b IN subtype. Considering such protocols and what is known about the
development of the V0 IN population can guide creation of a protocol to induce them from
pluripotent cells. Of the ventral progenitor subtypes, p0s arise furthest from the floor plate, and,
as it was previously shown that V0 INs can arise in the absence of Shh [54], it is plausible that
V0 INs can be generated in the absence of Shh signaling factors; the p0 marker, transcription
factor Dbx1, is also a class I transcription factor that is inhibited by Shh [72]. Therefore, when
first developing the V0 IN induction protocol, conditions with exposure to different
concentrations of RA without addition of Shh agonists (purm or SAG) were tested. After p0 and
V0V IN markers were detected in cultures only exposed to RA, activation of Shh signaling and
inhibition of Notch signaling were also examined and were found to increase the proportion of
cells expressing V0V IN markers.
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2.3 Materials and Methods
2.3.1 ESC Maintenance

RW4 mouse embryonic stem cells (ATCC, SCRC-1018) were maintained in T-25 flasks coated
with 0.1% gelatin (MilliporeSigma, G1393; in water) in complete medium containing 1000
U/mL leukemia inhibitory factor (LIF; MilliporeSigma, ESG1106) and 100 μM βmercaptoethanol (BME; Thermo Fisher Scientific, 21985023) at 37°C in 5% CO2. mESCs were
passaged by dissociating colonies with 0.25% trypsin ethylenediaminetetraacetic acid (trypsinEDTA; Thermo Fisher Scientific, 25200072) for five minutes followed by quenching and
trituration with excess complete medium. Single cells were plated in a new flask containing
complete medium +LIF +BME at a 1:5 ratio for two days or until ~80% confluent.

2.3.2 Media Formulations
Complete medium: Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher Scientific,
11965; +L-Glutamine, high glucose) containing 10% newborn calf serum, 10% fetal bovine
serum, 1x nucleoside solution (10 μM thymidine, and 30 μM of adenosine, cytosine, guanosine,
and uridine).

DFK5 medium: DMEM/F12 (Thermo Fisher Scientific, 11320; +L-Glutamine, +Sodium
Pyruvate, –HEPES, high glucose) containing 5% knockout serum replacement (Thermo Fisher
Scientific, 10828), 1x Insulin, Transferrin, Selenium Solution (Thermo Fisher Scientific, 41400;
1.72 µM Insulin, 68.8 nM Transferrin, 38.7 nM Sodium Selenite), 0.5x non-essential amino acid
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solution (50 µM of each amino acid), 0.5x nucleoside solution (5 μM thymidine, 15 μM of
adenosine, cytosine, guanosine, and uridine), and 55 µM BME.

Neuronal medium: DFK5 medium and Neurobasal medium (Thermo Fisher Scientific, 21103),
1:1 (v/v) ratio.

2.3.3 V0V Interneuron Induction and Culture

Please note that the following protocol is the final protocol determined through the work
presented in this publication. Please refer to Results, section 2.4 for descriptions of variations in
testing protocol parameters.

RW4 mESCs were dissociated with 0.25% trypsin-EDTA, quenched with complete medium, and
counted. 3 x 106 single cells were pelleted at 300xg, the medium was aspirated, and the cells
were suspended in 10 mL DFK5 medium in a 10 cm tissue culture-treated dish coated with 0.1%
agar (in water) to allow for embryoid body (EB) formation. After 2 days (2-), EBs in DFK5
medium were collected into a 15 mL conical tube and allowed to settle for 10 minutes. The
medium was aspirated, and 10 mL of fresh DFK5 medium was used to resuspend the settled EBs
and return them to the agar-coated dish. After another 2 days (4-), ~30 µL of EBs per cm2 were
settled (e.g. for a 10 cm dish, settle 2.5 mL of EBs) in a 15 mL conical tube for 10 minutes. Old
medium was aspirated and 10 mL of fresh DFK5 +1 µM all-trans retinoic acid (RA;
MilliporeSigma, R2625: resuspended as a 20 mM stock in dimethyl sulfoxide [DMSO;
MilliporeSigma, D2650]) +100 nM purmorphamine (purm; MilliporeSigma, 540223) was used
to resuspend settled EBs and plate them on a non-tissue culture-treated 10 cm dish coated with
0.1% gelatin. After 2 days (4-/2+), medium was aspirated and replaced with 10 mL of fresh
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DFK5 +1 µM RA +5 µM N-{N-(3,5-difluorophenacetyl-L-alanyl)}-(S)-phenylglycine-t-butylester (DAPT; MilliporeSigma, D5942: resuspended as a 10 mM stock in DMSO). Induction was
complete after another two days (4-/4+).

For cultures grown longer than 8 days, multi-well plates were coated with 0.01% poly-Lornithine (MilliporeSigma, P3655; in 10 mM borate buffer, pH 8.3), rinsed three times with
HEPES-buffered saline solution (HBSS, pH 7.2), and coated with 10 µg/mL laminin (natural
mouse; Thermo Fisher Scientific, 23017015; in HBSS). Induced cultures were dissociated with
0.25% trypsin-EDTA, quenched with complete medium, counted, and plated on laminin-coated
wells at a range of densities, depending on the end-point (to account for proliferation, see Table
S1), to achieve ~1 x 105 cells/cm2 in neuronal medium supplemented with 1x B-27 supplement
(Thermo Fisher Scientific, 17504044), 1x GlutaMAX (Thermo Fisher Scientific, 35050061), and
5 ng/mL for each of brain-derived neurotrophic factor (BDNF, recombinant human, PeproTech,
450-02: resuspended as a 10 µg/mL stock in 0.1% bovine serum albumin [BSA, MilliporeSigma,
A2058] in phosphate buffered saline [PBS]), glial cell line-derived neurotrophic factor (GDNF,
recombinant human, PeproTech, 450-10: resuspended as a 10 µg/mL stock in 0.1% BSA in
PBS), and neurotrophin-3 (NT-3, recombinant human, PeproTech, 450-03: resuspended as a 10
µg/mL stock in 0.1% BSA in PBS). For cultures grown past day 12, cells were grown in
Neurobasal medium (Thermo Fisher Scientific, 21103049) supplemented with 1x B-27, 1x
GlutaMAX, and 5 ng/mL BDNF, GDNF, and NT-3.
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2.3.4 Isolation of RNA, Reverse Transcription, and qPCR

To collect cultured cells for qPCR analysis, medium was aspirated and cells were detached by
addition of 0.25% trypsin-EDTA followed by quenching and dissociation in complete medium.
Cells were pelleted at 300xg. All medium was aspirated, and pellets were resuspended in RLT
buffer as provided from the RNeasy Mini Kit (Qiagen, 74106). Pellets were either frozen at 80°C or immediately used with the RNeasy kit to isolate RNA per manufacturer instructions. 250
ng or 500 ng of RNA was reverse transcribed using the High-Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific, 4368813) per manufacturer instructions.

For qPCR, a solution of ultrapure water, TaqMan Fast Advanced Master Mix (Thermo Fisher
Scientific, 4444963), a TaqMan probe against mouse β-actin as a reference gene (Thermo Fisher
Scientific, Mm02619580_g1, using VIC-MGB_PL dye), and the TaqMan probe against the
target gene using FAM-MGB dye (Dbx1: Mm02344179_m1; Evx1: Mm00433154_m1) was
prepared and loaded into MicroAmp Fast Optical 96-Well Reaction Plate (Thermo Fisher
Scientific, 4346906) before loading each sample in triplicate. Plates were sealed, spun briefly to
remove bubbles, and loaded into the QuantStudio 3 instrument for measurement. The fold
change in mRNA expression levels were calculated using the comparative CT method (2^-ΔΔCT
values) with β-actin as the reference gene relative to uninduced cultures as the reference sample.

2.3.5 Immunocytochemistry and Image Analysis

Cultures were plated on 48-well, laminin-coated plates for immunocytochemistry (ICC) analysis.
Day 8 time point cultures were plated for 2-4 hours before fixation, day 10 cultures were plated
for 2 days and day 12 cultures for 4 days before fixation. Long-term cultures for examining
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mature neuronal markers were grown until either day 16 or day 22 (8 or 14 days post-induction).
Wells were rinsed once with PBS after aspirating the culture medium, then cells were fixed in
4% paraformaldehyde (PFA; MilliporeSigma, P6148) in 0.1M phosphate buffer for 20 minutes at
room temperature. Cells were then exposed to 2% normal goat serum (NGS; MilliporeSigma,
G9023) with 0.1% Triton X-100 (MilliporeSigma, X100; in PBS) to permeabilize and block for
30 minutes at room temperature. Primary antibodies (see Table 2.1) were diluted in 2% NGS
with 0.1% Triton X-100 and cells were stained overnight at 4°C. Primary antibody solutions
were removed and cells were washed 3 times for 10 minutes per wash with PBS. Secondary
antibodies (see Table 2.2) were diluted in 2% NGS with 0.1% Triton X-100 and then filtered
with a 0.22 µm PVDF syringe filter (MilliporeSigma, SLGV033RS). After adding secondary
antibodies, plates were wrapped in foil and the cells were incubated for 1 hour at room
temperature. Secondary antibody solutions were removed and cells were washed 3 times for 10
minutes per wash with PBS. Cells were then stained in 1:1000 Hoechst 33258 (Thermo Fisher
Scientific, H3569; in PBS) for 10 minutes, rinsed once with PBS, then imaged with a DFC9000
GT camera (Leica) mounted on a DMi8 inverted widefield microscope (Leica) using a SOLA
Light Engine light source (Lumencor).

Images were analyzed using a CellProfiler pipeline to determine the percentage of cells costained for βIII tubulin, Evx1, and Lim1 [178,179]. At least 2 images each were taken from at
least 2 wells for each condition at each time point with N = 3-6.
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2.3.6 Flow Cytometry

Cultures were plated on multi-well, laminin-coated plates for flow cytometry analysis. Before
collection, day 8 time point cultures were plated for 2-4 hours, day 10 cultures for 2 days and day
12 cultures for 4 days. For collection, medium was aspirated and cells were detached by addition
of 0.25% trypsin-EDTA followed by quenching and dissociation in complete medium. Cells
were spun at 400xg for 5 minutes, medium aspirated, and pellets were resuspended in 4% PFA in
0.1M phosphate buffer to fix for 10 minutes at room temperature. Before staining, samples were

Table 2.1: Primary antibodies used for ICC and flow cytometry
Target

Final concentration Source, product number
or dilution used

Evx1

0.5 µg/mL

Developmental Studies Hybridoma Bank, 99.1-3A2a

Evx1

1 µg/mL

Biorbyt, orb183448b

Lim1

1a, 5b µg/mL

Developmental Studies Hybridoma Bank, 4F2

βIII tubulin 1 µg/mL

Biolegend, 845501a

βIII tubulin 0.5 a, 1b µg/mL

Biolegend, 802001

Hb9

2 µg/mL

Developmental Studies Hybridoma Bank, 81.5C10

Olig2

1:500 dilution

MilliporeSigma, MABN50

Dmrt3

5 µg/mL

Thermo Fisher Scientific, BS-4264R

MAP2

1:1000 dilution

MilliporeSigma, AB5622

VGLUT2

1:3000 dilution

MilliporeSigma, AB2251-I

NeuN

1:50 dilution

MilliporeSigma, MAB377

Chx10

0.2 µg/mL

Santa Cruz Biotechnology, Inc., sc-374151

En1

2 µg/mL

Developmental Studies Hybridoma Bank, 4G11

a

Used for ICC

b

Used for flow cytometry
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divided and pelleted at 400xg. For staining with βIII tubulin antibody, samples were resuspended
in 5% NGS with 0.1% saponin (% w/v; MilliporeSigma, S4521) in PBS to permeabilize and
block for 20 minutes at room temperature (see Figure 2.S3). For staining with all other
antibodies, samples were resuspended in 5% normal NGS with 0.1% Triton X-100 (% v/v;) in
PBS to permeabilize and block for 20 minutes at room temperature. Primary antibodies (see
Table 2.1) were diluted in 2% NGS in PBS and cells were stained for 1 hour at room
temperature. Primary antibody solutions were removed and cells were washed 3 times for 10
minutes per wash with PBS. Secondary antibodies (see Table 2.2) were diluted in 2% NGS with
in PBS and then filtered with a 0.22 µm PVDF syringe filter. After adding secondary antibodies,

Table 2.2: Secondary antibodies used for ICC and flow cytometry
Targeta

Conjugated fluorophore Final concentration Product numberb

Mouse IgG2a

Alexa Fluor 488

4 µg/mL

A-21131

Mouse IgG2a

Alexa Fluor 555

4 µg/mL

A-21137

Mouse IgG2a

Alexa Fluor 647

4 µg/mL

A-21241

Mouse IgG1

Alexa Fluor 488

4 µg/mL

A-21121

Mouse IgG1

Alexa Fluor 555

4 µg/mL

A-21127

Guinea pig IgG Alexa Fluor 488

4 µg/mL

A-11073

Mouse IgG

Alexa Fluor 647

4 µg/mL

A-21236

Rabbit IgG

Alexa Fluor 488

4 µg/mL

A-11008

Rabbit IgG

Alexa Fluor 647

4 µg/mL

A-21244

a

All secondary antibodies were from goat hosts

b

All secondary antibodies were purchased from Thermo Fisher Scientific
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samples were protected from light while incubating for 1 hour at room temperature. Secondary
antibody solutions were removed and cells were washed 3 times for 10 minutes per wash with
PBS. Cells were resuspended in PBS for measurement on an Attune NxT Flow Cytometer
(Thermo Fisher Scientific).

Figure 2.S3: Gating strategy for flow cytometry data for samples immunostained with βIII
tubulin versus other stains
Samples as measured in Figure 2.3E,F were divided, with part being permeabilized with saponin
before staining with βIII tubulin, and the other part being permeabilized with Triton X-100 before
staining with Evx1 and Lim1 (see Materials and Methods section for details) and for examination of
other populations (Figure 2.4). Cells were identified by Forward Scatter Height and Side Scatter
Height plots and singlets were identified by Forward Scatter Area versus Forward Scatter Height
plots. Singlets from samples incubated with only secondary antibody were used to generate negative
gates, and samples stained with primary and secondary antibodies were measured based on these
gates.

2.3.7 Microelectrode Array Recordings Including mESC-Derived MN Coculture

A CytoView 24-well microelectrode array (MEA) plate (Axion Biosystems, M384-tMEA-24W5) containing 16 microelectrodes per well was used for recordings on a Maestro Edge instrument
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(Axion Biosystems). Electrode areas were coated with 0.01% poly-L-ornithine followed by
washing with HBSS and coating with 5 µg/mL laminin before plating cells at 1 x 105 cells/well.

Day 8 mESC-derived V0V IN inductions were dissociated with 0.25% trypsin-EDTA, quenched
with complete medium, then pelleted at 400xg. After aspirating medium, cells were resuspended
in 1 mL of Neuronal medium containing supplements and counted.

MNs derived from RW4 mESCs were used as a co-culture population, with induction starting on
day 2 of V0V IN inductions. For MN induction, RW4 mESCs were dissociated with 0.25%
trypsin-EDTA, quenched with complete medium, and counted. 1 x 106 single cells were pelleted
at 300xg, the medium was aspirated, and the cells were suspended in 10 mL DFK5 medium in an
agar-coated 10 cm tissue culture-treated dish to allow EBs to form. After 2 days (2-), EBs in
DFK5 medium were collected into a 15 mL conical tube and allowed to settle for 10 minutes.
After aspirating medium, 10 mL of fresh DFK5 medium containing 2 µM RA and 500 nM SAG
(MilliporeSigma, 566661) was used to resuspend EBs and return them to the dish. The procedure
on day 2 was repeated on day 4 (2-/2+). MN induction was complete on day 6 (2-/4+). Cells were
dissociated, pelleted, and resuspended in 1 mL of Neuronal medium with supplements before
counting.

Wells were seeded at a density of 1 x 105 cells/10 µl droplet of Neuronal medium with
supplements; for co-cultures, MN:V0V IN ratios were tested at 1:1 and 1:4. After allowing
seeding for 4 hours, additional supplemented Neuronal medium was added to the well slowly to
reduce detachment of cells. Medium was refreshed by half volumes every 2 days. For days 12
onward, medium was exchanged with Neurobasal supplemented with B-27, growth factors, and
GlutaMAX in the above-mentioned amounts.
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Recordings were taken for 10 minutes every 2 days for spontaneous activity for 5 min, followed
by an electrical stimulus and another 5 minutes of recording. On day 16 of V0V IN culture, some
wells were exposed to 30 µM 1,2,3,4-Tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7sulfonamide (NBQX) disodium salt hydrate (MilliporeSigma, N183-5MG: resuspended as a 1 M
stock in water) to observe changes in activity. Baseline recordings were taken, followed by
incubation in drug for 20 minutes, a recording during drug exposure, and then a washout period
followed by a final recording 20 minutes later.

2.3.8 Statistics

GraphPad Prism version 7 and Microsoft Excel were used for statistical analyses. Outliers were
identified and excluded using the ROUT method with Q=5% in Prism; briefly, this method first
uses a robust curve fit from a Lorenzian distribution – which, with long tails, is not impacted by
outliers – using Q as a false discovery rate to determine outliers from the residuals and then uses
least-squares regression on the remaining data. Values are reported as means and error bars are
standard error of the mean (S.E.M.). One-way analysis of variance (ANOVA) using Scheffe’s
multiple comparison method with 95% confidence was used to determine significance, which is
indicated in figures as follows, unless otherwise stated: * for p < 0.05, ** for p < 0.01, *** for p
< 0.001, and **** for p < 0.0001.
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2.4 Results
2.4.1 Generating V0 Progenitor and IN Marker-Expressing Cells from
mESCs

With the goal of achieving a protocol specific to deriving V0 INs from mESCs, different
induction conditions were tested by modifying procedures known to produce V2a INs and MNs
[82,102]. By first culturing embryoid bodies (EBs) through growing mESCs in suspension for
either 2 or 4 days (known as 2- or 4-, see Figure 2.2A), embryogenesis is stimulated as well as the
beginning of lineage specification, including neurogenesis. The EBs are then exposed to RA,
which is involved in inducing neuralization and in caudalization towards a spinal fate. Several
concentrations of RA were tested at amounts known to induce spinal neurons [102,120,121]. To
determine whether these conditions effectively generated cells expressing V0 progenitor and IN
markers, cultures were collected for qPCR analysis. As seen in Figure 2.2B, 2 days of EB
formation followed by 4 days of exposure to RA resulted in a significant decrease in Dbx1
(progenitor) mRNA expression at all concentrations tested except 4 µM RA and little change in
Evx1 (V0V INs) mRNA expression over uninduced cultures grown under the same conditions
without RA exposure. However, allowing 4 days of EB formation produced a significant
increase in the Dbx1 mRNA expression versus uninduced cultures after exposure to 1 or 2 µM
RA for 2 days (4-/2+, Figure 2.2C). Another 2 days of RA exposure (4-/4+) generated a significant
increase in Evx1 mRNA expression over uninduced cultures at 1 µM RA (Figure 2.2D). In
accordance with previous observations in the literature of transient progenitor and post-mitotic
V0 IN markers during development, both Dbx1 and Evx1 mRNA were transiently expressed, and
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relative expression of these markers was greatly reduced over the ensuing four days (Figure
2.S1) [55,56,170]. Based on these data, a 4-/4+ protocol using 1 µM RA was used in further
protocol development.

Figure 2.S1: Transient mRNA expression of progenitor (Dbx1) and post-mitotic (Evx1)
V0 markers
After 4 days of EB formation, cultures were induced with 1 µM RA for either 2 (for the 4-/2+
time point) or 4 days (other time points), then collected for qPCR analysis at the time points
shown. --- line delimits upregulation, ··· line delimits downregulation. Error bars are S.E.M.,
N = 4-18. Significance is reported as follows: * denotes p < 0.05 between samples indicated,
** denotes p < 0.01 between samples indicated. For Evx1 mRNA expression, 4-/4+ versus day
10, p = 0.145 and for 4-/4+ versus day 12, p = 0.058.

2.4.2 Improving Expression of V0V IN Subtype Markers in the Population

Although V0 progenitor and IN markers were induced when cultures were exposed only to RA,
we wanted to determine the effect of Shh signaling, as it is known to be involved in ventral
progenitor IN domain specification. Also, within the different IN populations, there exist many
subtypes where the specification of some subtypes (i.e. V2a versus V2b) depends in part on
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Notch signaling. Therefore, to see if Shh and Notch signaling had an effect on the specification
of V0V INs, various conditions were tested with small molecule effectors for these pathways.
The weak smoothened agonist purmorphamine (purm) was used to stimulate Shh signaling while
the gamma-secretase inhibitor DAPT was used to impede Notch signaling.

To observe effects of Shh signaling on V0 IN induction,
changes to both Dbx1 and Evx1 mRNA expression were
measured. Initially, 4-/2+ cultures induced with 1 µM RA
were examined to see the effects of different purm
concentrations on V0 progenitor marker Dbx1 mRNA
expression after exposure from days 4 to 6; 10 nM and 100
nM purm did not significantly affect Dbx1 mRNA
expression, while 1 µM purm, a concentration used to
induce V2a INs from mESCs, significantly decreased Dbx1
mRNA expression (Figure 2.2E) [82]. To examine Shh
signaling in V0V IN induction, 4-/4+ cultures induced with 1
µM RA were exposed to 100 nM purm for different
intervals (see Figure 2.S2). Some of these cultures were

Figure 2.S2: Schematic for
testing addition of purm (to
stimulate Shh signaling) and
DAPT (to inhibit Notch
signaling) to the 4-/4+ induction
After 4 days of EB formation,
inductions cultured with 1 µM RA
were tested with/without exposure
to 100 nM purm at various time
intervals as shown by the grayed
intervals as well as with/without 5
µM DAPT from days 6 to 8 as
shown by the hatched intervals.
Related to Figure 2.2F.

also treated with 5 µM DAPT at the latter part of induction
to determine whether Notch plays a role in V0V IN induction as well. Figure 2.2F shows that
exposure to 100 nM purm from days 4 to 6 or 5 to 8 with addition of DAPT from days 6 to 8
resulted in the greatest increase in Evx1 mRNA expression (64.9-fold or 60.8-fold over
uninduced cultures, respectively). These conditions also resulted in significantly greater Evx1
mRNA expression over induction with RA
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Figure 2.2: Generating V0 progenitor and IN marker-expressing cells from mESCs
(A) Schematic of the time course for induction of mESCs toward V0 IN fate. mESCs were suspended
in agar-coated plates to allow formation of EBs for either 2 (2-) or 4 (4-) days. EBs were then plated on
gelatin and exposed to RA for either 2 (2+) or 4 (4+) days before collection for qPCR analysis. (B - D)
mRNA expression of progenitor marker Dbx1 (green bars) and post-mitotic V0V subtype marker Evx1
(blue bars) in cells collected after inductions using various concentrations of RA for (B) 2-/4+, N = 411; (C) 4-/2+, N = 4-14; or (D) 4-/4+, N = 5-18. Values are given as fold change relative to uninduced
cultures grown under the same conditions but without exposure to RA. Significance is reported for the
same gene at the same time point: * denotes p < 0.05 vs uninduced, ** denotes p < 0.01 vs uninduced.
For (E) and (F), mESCs were allowed to form EBs for 4 days. Cultures were then grown on gelatin
and exposed to 1 µM RA from day 4 until day 6 (E) or day 8 (F). (E) At day 4, inductions (cont’d)
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were tested with exposure to log-fold concentrations of purm up to 1 µM, which is known to induce
V2a INs in vitro. Cultures were analyzed at 4-/2+ for Dbx1 mRNA expression. N = 8-9. Significance is
reported as follows: ** denotes p < 0.01 compared to other conditions shown. (F) Evx1 mRNA
expression evaluated at day 8 after exposure to 100 nM purm at various time points as shown on the xaxis (see Figure 2.S2) and/or 5 µM DAPT from days 6 to 8. N = 4-11. Significance is reported as
follows: * denotes p < 0.05 vs only RA, ** denotes p < 0.01 vs only RA, and **** denotes p < 0.0001
vs only RA; †† denotes p < 0.01 for indicated samples vs induction with RA and DAPT. For both (E)
and (F), values are given as fold change relative to uninduced cultures grown under the same
conditions but without exposure to morphogens. Error bars are S.E.M. and --- line delimits
upregulation, ··· line delimits downregulation.

and DAPT without purm, suggesting that affecting both Shh and Notch signaling is important for
achieving a greater level of V0V IN induction. Based on qPCR data of the conditions tested, the
most efficient method of inducing Evx1 mRNA expression from mESCs is using a 4-/4+ protocol
with addition of 1 µM RA from days 4 to 8, 100 nM purm from days 4 to 6, and 5 µM DAPT
from days 6 to 8.

2.4.3 Quantifying Proportion of Cells Expressing Markers for V0V INs at
Different Time Points

To ensure induction of cells expressing V0V IN markers, we examined cultures by ICC with
antibodies against Evx1, Lim1, and the pan-neuronal marker βIII tubulin. Lim1 was used to
distinguish the Lim1+ V0V INs from a dorsal IN population, dI1, which also transiently expresses
Evx1 during development but is Lim1- [54]. Uninduced cultures, 4-/4+ cultures with only RA,
and 4-/4+ cultures with RA, purm, and DAPT were stained after dissociation and plating on
laminin-coated plates. Cell were plated at lower densities for day 10 and day 12 cultures to
account for cell proliferation (see Table 2.S1); however, final cell densities were still variable
and often higher at the later time points, especially in uninduced cultures. Cultures were fixed on
days 8, 10, and 12: Figures 2.3A-C show representative images of each condition and time point.
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Table 2.S1: Cell densities reported per cm2 as plated on day 8 depending on endpoint and
induction method to account for cell proliferation

Endpoin
t

Induction method
Uninduced

4-/4+ RA

4-/4+ RA, purm, DAPT

Day 8

1x105

1x105

1x105

Day 10

6x104

8x104

1x105

Day 12

4x104

6x104

8x104

Images were analyzed using a CellProfiler pipeline to determine the proportion of “triple
positive” cells expressing βIII tubulin, Evx1, and Lim1 (Figure 2.3D). Triple positive cells were
greatest in day 10 cultures grown with RA, purm, and DAPT, with approximately 44% of cells
expressing V0V IN markers. As an additional measurement of the proportion of cells expressing
V0V IN markers, we stained uninduced cultures and 4-/4+ cultures exposed to only RA or RA,
purm, and DAPT on days 8, 10, and 12 and analyzed them by flow cytometry (Figure 2.3E, F).
Flow data show that addition of RA, purm, and DAPT significantly increases the percentage of
cells expressing Evx1 and Lim1 at days 10 and 12 over uninduced cultures. At day 10, ~57% of
RA, purm, DAPT-induced cells express Evx1 and Lim1 (Figure 2.3E) while 60% of cells are
positive for βIII tubulin (Figure 2.3F) – this proportion is comparable to the values seen by ICC
analysis.

2.4.4 Determining Presence of Other Cell Types after 4-/4+ V0V IN Induction

To examine the composition of the resultant heterogenous culture produced through the 4-/4+
induction with RA, purm, and DAPT, cells were probed by immunostaining (Figure 2.4). By day
8, V0V IN inductions yielded 36% of cells co-expressing Evx1 and Lim1 (Figure 2.3E). The
populations that arise adjacent to the V0 INs are the dI6 and V1 INs and are marked by Dmrt3
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Figure 2.3: Quantifying proportion of cells expressing markers for V0V INs at different time
points
mESCs were induced with 4-/4+ protocol and fixed on day 8, day 10 or day 12; cultures were
dissociated on day 8 and thereafter grown on laminin-coated plates in supplemented Neuronal medium
until fixation 2-4 hours, 2 days, or 4 days later for day 8, day 10, and day 12 time points, respectively.
(A) Representative images of day 8, 10 and 12 cultures that were uninduced; exposed to 1 µM RA
only; or exposed to 1 µM RA, 100 nM purm from days 4 to 6 and 5 µM DAPT from days 6 to 8.
Staining for Evx1 is shown in red, Lim1 in green, and βIII tubulin in blue. Day 10 induction with RA,
purm, and DAPT at higher magnification is shown in (B). Day 12 uninduced culture at higher
magnification is shown in (C). For (B) and (C), channels are separated to show Hoechst stain of
nuclei, while composite images show co-expression of Evx1, Lim1, and βIII tubulin. Scale bars are 50
µm. (D) Percentages from ICC image analyses are given for the proportion of “triple positive” cells for
each condition on days 8, 10 and 12. At least 2 images of at least 2 technical replicates were taken for
each biological replicate: N = 3-6, n = 16-35. (E-F) Flow cytometry analysis of (E) Evx1+Lim1+ single
cells, N=11-13 and (F) βIII tubulin+ single cells, N = 8-9. For (D-F), error bars are S.E.M. and
significance is reported among samples of the same time point: ** denotes p < 0.01 vs uninduced; ††
denotes p < 0.01 for RA, purm, and DAPT vs only RA.

and En1, respectively (Figure 2.1A). In the day 8 cultures, 30.2% of cells were Dmrt3+, while
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15.8% were En1+, showing a large portion of the
other cells arising in the cultures are of the
adjacent IN populations (Figure 2.4A). V2a INs
can be identified by transient Chx10 expression,
and in these cultures, 6.1% were Chx10+. Hb9+
cells in the spinal cord largely include MNs but
also mark another CPG population of INs [180].
In day 8 V0V IN inductions, 11.6% of the cells
were Hb9+/Olig2-, suggesting either Hb9+ INs or
post-mitotic MNs are present, while 3% were
positive for both Hb9 and Olig2, showing the
presence of pMNs transitioning to post-mitotic
MNs. 2.4% of cells were Hb9-/Olig2+ cells
comprising pMNs and oligodendroglial
precursors. Representative ICC images
Figure 2.4: V0V IN induction cultures stain
for populations that arise adjacent to V0 INs
mESCs were induced with 4-/4+ protocol using
RA, purm and DAPT then fixed on day 8. (A)
Flow cytometry data showing the percent of
singlets staining positive for Dmrt3, En1,
Chx10, or Hb9/Olig2. Error bars are S.E.M.,
N=6-11. (B-E) Representative images of day 8
cultures stained for (B) Dmrt3 (green), (C) En1
(green), (D) Chx10 (green), or (E) Hb9 (green)
and Olig2 (red). Hoechst is shown in blue.
Scale bars are 50 µm. In (E), the red arrow
shows a Hb9-/Olig2+ cell, the green arrow
shows a Hb9+/Olig2- cell, and the yellow arrow
shows a Hb9+/Olig2+ cell.

examining these different populations can be
seen in Figure 2.4 B-E, affirming that the
majority of non-V0V IN marker-expressing cells
are neurons of the nearby developing neuronal
populations.
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2.4.5 Functionality and Maturation of mESC-Derived V0V IN Cultures

To generate PSC-derived INs that can fire action potentials and synapse onto and affect other
cells, V0V IN cultures were induced and examined at day 16 and day 22 for the presence of the
mature markers for neuronal nuclei, NeuN, and the dendritic marker MAP2, as well as VGLUT2
for glutamatergic cells (Figure 2.5A-D). Day 16 cultures were positive for the mature markers
examined, but compared to cultures at day 22, staining seems less organized with fewer NeuN+
cells co-staining with high levels of VGLUT2 (Figure 2.5A). By day 22, MAP2 staining
becomes more diffuse along the processes that have extended, and VGLUT2 appears to have
increased in cell bodies. Some VGLUT2 staining is seen along MAP2+ extensions (see Figure
2.5D). Based on such images, V0V IN inductions show maturation as NeuN, VGLUT2, and
MAP2 coincide in more cells at day 22 than at day 16.

In these cultures, because of the mixture of cells present, precisely determining the functionality
of the V0V INs - which by the time they mature will no longer be marked by their definitive postmitotic marker, Evx1 - cannot be done without a method of tracing or purification. However,
cultures were examined to get an overall sense of the presence of functional neurons by culturing
the inductions on MEA plates to observe spontaneous activity over time (Figure 2.5E, F). For
comparison, mESCs were also induced into heterogenous MN cultures following an established
2-/4+ protocol known to generate functional MNs that show maturation over time [134]. Cells
were also plated as mixed cultures in a ratio of either 1:1 or 1:4 MNs:V0V INs to allow
communication between the different cell types. The mean firing rate (MFR) of spontaneous
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Figure 2.5) V0V IN cultures show mature neuronal marker protein expression and
electrophysiological activity
4-/4+ cultures with RA, purm, and DAPT were plated on laminin-coated plates and grown up to 22
days. (A-D) Cultures showing expression of synaptic marker VGLUT2 (green), mature neuronal
marker NeuN (red), and dendritic marker MAP2 (blue). (A-B) Day 16, (C-D) day 22. (B) and (D)
show Hoechst in separated channels. Scale bars are 50 µm. (E-F) Cultures were plated on MEA plates
to examine spontaneous activity. Cells were plated at 1 x 105 cells per well/array and comprised MN,
V0V, a 1:1 ratio of MN:V0V INs, or a 1:4 ratio of MN:V0V INs. (E) Mean firing rate of MN, V0V,
MN:V0V1:1, and MN:V0V 1:4 cultures; N=2 with n=4-8 for each, error bars are S.E.M. Significance is
reported as follows: p < 0.05 for d16 vs days 8 and 10 for MN:V0V 1:4 cultures. (F) Representative
raster plots for a MN:V0V 1:4 culture showing baseline spontaneous activity, change in activity pattern
after 20-minute incubation in NBQX, as well as activity after subsequent washout.
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activity for MN cultures was ~0.2 Hz by day 16, which is on a similar scale to what was
observed in a study evaluating the contribution of different ventral INs in in vitro circuitoid
cultures [71]. V0V IN cultures’ spontaneous activity was around 0.4 Hz at day 16 (Figure 2.5E),
which is also on a similar scale to that observed of other ventral IN populations in vitro. The
MFR was much higher when MN and V0V IN cultures were grown together, and in MN:V0V 1:4
wells, increased to about 5 Hz by day 16 - a significant increase over day 8 and day 10
spontaneous MFRs in these cultures (Figure 2.5F). Little has been reported in the literature about
the in vitro MFR for spontaneous activity of V0V INs, but the V0C subpopulation has been
shown to have a firing rate around 3 Hz in spinal cord preparations [170]. Cultures were also
exposed to the AMPA/kainite receptor antagonist NBQX; a difference in spontaneous activity
was only observed in especially active 1:4 MN:V0 co-culture wells, which showed a decrease
after a 20-minute incubation (Figure 2.5F) [181]. Together, these data suggest that there are
glutamatergic cells present in the V0V IN cultures that contribute to an increased rate of firing
spontaneous action potentials through communication with MN cultures compared to lone MN
or V0V IN cultures.

2.5 Discussion
The objective of this study was to derive V0 INs from mESCs with a simple and short protocol.
While other inductions deriving MNs or IN populations from mESCs have used 2 days for EB
formation prior to exposure to morphogens, this study has shown that allowing 4 days of EB
formation produces higher V0 progenitor and V0V IN marker mRNA expression. Perhaps the
additional 2 days provides a necessary increase in cell layers in the EBs to better simulate the
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conditions of V0 progenitor development in vivo (positional depth in the tissue in combination
with morphogen concentration), as these cells are known to arise near the medial central canal.

Compared to established protocols to induce ventral neuronal populations, similar concentrations
of RA led to significant increases in V0 marker mRNA expression, with 1 µM RA producing the
greatest effect for inducing both the progenitor marker Dbx1 and the V0V IN marker Evx1.
Although exposure to only RA was sufficient to induce V0V IN marker Evx1 mRNA expression,
providing additional factors to stimulate Shh signaling and inhibit Notch signaling improved the
expression of this post-mitotic V0V IN marker significantly in the population (Figure 2.2F). For
Shh, the less potent purm was chosen over SAG to achieve signaling levels closer to those
known to induce V2a INs. It seems there is a threshold concentration for purm to affect V0
progenitor development, as the 10 and 100 nM concentrations had little effect on Dbx1 mRNA
expression over induction with only RA; exposure to 1 µM purm significantly reduced Dbx1
mRNA expression (Figure 2.2E). This idea is supported by previous work using 1 µM purm as
the concentration to induce mESCs to form V2a INs [82], a more ventral population exposed to a
higher concentration of Shh during specification. Also, previous studies have shown and
discussed that threshold effects contribute to the definition of the progenitor boundaries
[60,72,174,182,183]. Based on this effect seen on Dbx1 mRNA expression, further studies were
completed using 100 nM purm, the highest concentration tested without effect on Dbx1 mRNA
expression. It is possible that induction of cells expressing V0V IN markers would be enhanced if
further testing were completed to find the best concentration of purm for induction. Different
time courses of Shh stimulation through purm exposure showed that earlier addition at days 4 or
5 tended to yield higher Evx1 mRNA expression. However, addition of purm alone did not
significantly increase marker expression over induction with only RA; addition of the Notch
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inhibitor DAPT alone from days 6 to 8 also did not significantly increase Evx1 mRNA
expression over RA only cultures (Figure 2.2F). When both are present during the induction,
however, there is a synergistic effect producing significantly higher expression in all cultures
exposed to both factors relative to inductions only exposed to RA. Here, a later addition of
DAPT was tested, as subtype specification has been suggested to occur later in the
developmental timeline [184], as occurs with V2a versus V2b INs [47,77]. Other time courses of
DAPT exposure might alter Evx1 mRNA expression levels, but a brief examination of addition
of 5 µM DAPT from days 4 to 6 was also tested with no obvious changes over RA-only
induction in the proportion of V0V INs stained by ICC (data not shown).

While there is an approximately five-fold increase in Evx1 mRNA expression in cultures
exposed to RA, purm, and DAPT compared to only RA, exposure to these factors yields only a
modest increase in the number of cells co-expressing V0V IN protein markers Evx1 and Lim1.
This could be due to a few factors. First, as qPCR is a population assay, the relative amount of
mRNA measured could either increase slightly in a large number of cells or increase by a large
amount in a few cells. Therefore, the small increase in the proportion of cells expressing Evx1
protein as seen in Figure 2.3 might comprise cells that have a large increase in Evx1 mRNA
expression in a smaller population of cells instead of many cells expressing a slight increase in
Evx1 mRNA. Second, the percentage of cells co-expressing Evx1 and Lim1, not just Evx1 alone,
is reported; there are some cells that only express Evx1 or only express Lim1, but these values
are not reported as this protocol seeks to generate cells co-expressing these proteins. It is possible
that using these immunofluorescent assays to measure the V0V IN population has missed some
cells that once expressed Evx1 but have already turned off its expression, as Evx1 is known to be
transiently expressed [56,170]. This idea is supported by transient Evx1 mRNA expression
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observed over different time points (Figure 2.S1). The decrease in the “triple positive” cells by
day 12 as seen in Figure 2.3D is likely due to a combination of this transient expression of Evx1
as well as a change in the proportion of βIII tubulin+ cells present. At day 10, the morphogen
exposure during induction has driven many of the cells toward a neuronal fate, especially when
DAPT is present, as it is known to enhance neuronal differentiation [185]. This can be seen as a
shift to an earlier peak of βIII tubulin+ cells in the RA, purm, DAPT induction versus the RA
only or uninduced cultures (Figure 2.3F). Also, there are Hb9-/Olig2+ cells present (Figure 2.4A),
which are glial lineage cells that proliferate, resulting in a smaller ratio of post-mitotic neurons
by day 12. The composition of the induction culture was examined at the day 8 time point
because it is the end of induction, when the cultures have the largest ratio of βIII tubulin+ cells,
which could give the most representative distribution of cell populations before glia begin to
proliferate.

The cultures produced through the protocol presented in this article make a heterogenous mixture
including cells that express markers for the population of interest, V0V INs. However, marker
expression alone does not ensure that there are functional neurons present. To show functionality
of a heterogenous culture is difficult without using a lineage-traceable cell line to identify the
V0V IN population from the culture is problematic, thus patch-clamping for single-cell
electrophysiological characterization is difficult when individual V0V INs cannot be identified
while alive. Therefore, MEAs were used an alternative means to ascertain that functional
neurons are present after induction, although specifying which cells are directly contributing to
functionality is not possible using this system. However, if the V0V IN population could be
purified from the heterogenous mixture, MEA data could provide more precisely determine V0V
IN functionality – see Chapter 3, Figures 3.5 and 3.6. In this study, heterogenous MN cultures
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were used both as a comparison for heterogenous V0V IN cultures as well as to provide a
correspondent population, as the MN cultures produced have been shown to include functional
MNs that demonstrate maturation over time [134]. The MEA data show that MN and V0V IN
heterogenous cultures have limited spontaneous activity on their own (Figure 2.5E), which was
not entirely expected since other cell types are present that could communicate with the V0V INs,
including En1+ (V1 INs), Chx10+ (V2a), and Hb9+ (MN or “Vx” INs) cells. This supports the
idea that finding an appropriate ratio of different CPG-associated cell types is necessary to elicit
more robust spontaneous electrophysiological activity. Here, 1:1 and 1:4 ratios of MN:V0V INs
were tested, and the MFRs were comparable between these groups, with the 1:4 ratio achieving a
significantly higher rate at day 16 over days 10 and 8, suggesting maturation and communication
between the different cells present in the mix. Because the cultures include proliferative cells,
they become overcrowded by about 2 weeks post-induction (data observed, not shown),
emphasizing the need for purified cultures for longer term studies.

ICC of V0V IN cultures at day 16 and day 22 using the dendritic marker MAP2, glutamatergic
marker VGLUT2, and neuronal marker NeuN show cells expressing all three markers at both
time points. However, although not quantified, the number of cells co-expressing these mature
markers was observed to be fewer at day 16 compared to day 22, suggesting maturation over this
6 day period. MAP2 staining was intense and constricted at day 15, whereas it became weaker
and more widespread by day 22, which follows inference, as more mature cultures have more
extensive neuronal processes. However, since MAP2 is known as a dendritic marker, the
presence of MAP2 in longer processes suggests a degree of immaturity. The antibody used to
detect MAP2 detects all isoforms of MAP2, including MAP2C, which is known to be expressed
in axons in less mature neurons and is later downregulated in preference for MAP2A and B
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isoforms expressed mainly in dendrites [45]. The presence of glutamatergic cells was also
determined through suppression of spontaneous activity in the presence of the AMPA/kainite
blocker NBQX. Bursts of action potentials were seen before exposure to NBQX (Figure 2.5F),
which were obliterated after exposure. Together, ICC and MEA data suggest that the
glutamatergic cells present have an important role in spontaneous electrophysiological activity in
these cultures, including contributing to the bursting activity observed.

The data presented in this study have shown that the derived cells include those that express V0V
IN markers and glutamatergic markers, and neurons firing spontaneous action potentials;
however, other cell types are also induced in these cultures, which obscures any observations on
the function of V0V INs obtained from utilizing the induced cultures in further studies.
Therefore, a means of purification of V0V INs from the heterogeneous population is desirable. A
high-purity culture of V0V INs would provide a tool for investigators for use in studies including
analyzing spinal microcircuits in a controlled manner, such as in MEAs or microdevices, or after
transplantation in animal models to determine whether V0V INs contribute to any functional
recovery in injury or disease models. Recently, neural progenitor cells and high-purity V2a INs
were transplanted in a cervical level contusion spinal cord injury rat model, and rats receiving the
V2a INs showed increased functional recovery over other groups [84]; this shows the utility of
obtaining a large, high-purity population of INs and the promise of their therapeutic potential.

This study has provided the first step for future investigations using isolated V0V INs: a method
of obtaining a high proportion of V0V INs from a renewable source with a simple 8 day induction
protocol. The use of this protocol might be expanded to use in human PSCs. Other spinal
populations, MNs and V2a INs for example, have been derived from mESCs as well as from
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human pluripotent cells [83,104]; V0V INs could potentially be derived from human pluripotent
cells using a modified version of this protocol, bringing this research a step closer to translational
therapeutics.
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Chapter 3: A Transgenic Mouse Embryonic
Stem Cell Line for Puromycin Selection of
V0V Interneurons from Heterogenous
Induced Cultures
3.1 Abstract
Spinal interneurons (INs) are an important contributing population to our body’s normal
function. They relay sensory and motor control information between the brain and the body, and
when this relay circuitry is disrupted from injury or disease, it can be devastating to patients due
to the lack of native recovery in central nervous system (CNS) tissues. To better understand the
role of INs in normal function and as potential therapies for CNS injury and disease, obtaining a
large, relatively pure population is necessary for controlled study and use. The ventral V0 (V0V)
IN population is an excitatory population involved in locomotor circuits and is thus of interest as
a population in CNS studies. To achieve a scalable population of V0V INs, they can be derived
from pluripotent sources, such as mouse embryonic stem cells (mESCs), but the resultant culture
is heterogenous, obscuring the specific role of V0V INs. By generating a transgenic, selectable
mESC line, purifying V0V INs from mESC-derived culture is possible while still allowing
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scalability to improve their use in controlled studies. Herein describes the process of generating a
selectable mESC line to obtain a purified population of V0V INs, determining the composition of
the resultant selected cultures, observation of V0V IN maturation, and recording their functional
activity.

3.2 Introduction
Spinal cord injury (SCI) persists as a devastating infliction for patients as doctors and researchers
have yet to find a widely efficacious method to treat injured spinal cord tissue. An underlying
hinderance in SCI treatment is the loss of neurons, which form connections between the body
and the brain, as they are post-mitotic and have limited regenerative capacity. To reconnect the
lost circuits, cell transplantation is a potential method of introducing cells to the injury site to
support growth of spared neurons through release of neurotrophic factors and for cell
replacement. For cell transplantation, several cell lineages have been investigated to determine
their contribution to repair (see this review for more information: [186]), but the propriospinal,
interneuron (IN) populations have been shown to create local connections post-injury [11–13].
INs are classified as dorsal or ventral, which contribute largely to sensory or motor function,
respectively [36], and several studies have worked toward deconstructing the role of the different
IN subtypes and the interplay between them which drives normal function [16], as well as their
potential as therapeutic populations [186]. Many of these studies utilized knockdown or
knockout animal models, but such methods may obscure the functional contribution of a
population through possible redundancies or compensations inherent to spinal circuits [187,188],
requiring additional, alternative methods using particular IN populations in isolation. Such
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isolation would allow for more controlled studies but would require some method of purification
for the population of interest from its source.

V0 INs are of interest as a therapeutic population. They comprise a diverse set of INs that arise
from a Dbx1+ progenitor pool [54,55], and include excitatory, ventral V0 (V0V) INs – which
express transcription factor Evx1 [56] - and inhibitory, dorsal V0 (V0D) INs, with both ipsilateral
and commissural projecting axons. V0 INs contribute to left-right alternation [58,169], with V0D
INs shown to contribute more at lower locomotor frequencies and V0V INs contribute at higher
frequencies in rodents [58]. A subset of V0V INs expresses the transcription factor Pitx2 and
includes an ipsilateral population that project onto motor neurons (MNs) [57]. These Pitx2+ cells
include the cholinergic V0C and glutamatergic V0G populations, with V0C involved in taskdependent excitation of MNs [57]. The contribution of V0V INs as an excitatory population
involved in locomotor circuits, including cells that project onto MNs, is therefore of great appeal
for cell replacement therapies.

For an abundant source of INs, one could differentiate them from pluripotent stem cells (PSCs),
including patient-derived induced PSCs (iPSCs) and embryonic stem cells (ESCs), into the
desired neuronal type. Induction protocols to obtain neurons from PSCs, however, are not
completely efficient – often with less than half the culture comprising the cells of interest - thus
requiring a method to purify the intended population from the heterogenous culture. For
example. our recent induction protocol generating V0V INs from mouse ESCs (mESCs) yielded
approximately 40% of the cells expressing V0V IN markers 2 days post-induction (Figure 2.3)
[103]. To purify the cell population of interest from such heterogenous inductions, our lab has
generated transgenic mESC lines that use an IN- or MN-specific gene marker to drive expression
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of a puromycin-specific selection marker, puromycin-N-acetyltransferase (PAC)
[125,126,133,159]. As the induced mESCs become the intended INs expressing their specific
gene marker, it drives expression of PAC and thus renders those cells insensitive to puromycin
exposure while other cells in the culture succumb. In this article, a mESC line used to select V0V
INs by insertion of PAC into the Evx1 locus is analyzed for efficiency of selection, remaining
proliferative cells and other IN populations, and maturation and electrophysiological
characterization of selected V0V IN populations.

3.3 Materials and Methods
3.3.1 Cell Culture Media Formulations
Complete medium (CM): Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher
Scientific, 11965; +L-Glutamine, hi glucose) containing 1x nucleoside solution (10 μM
thymidine, and 30 μM of adenosine, cytosine, guanosine, and uridine), 10% fetal bovine serum,
and 10% newborn calf serum.

DFK5 medium: DMEM/F12 (Thermo Fisher Scientific, 11320; +L-Glutamine, +Sodium
Pyruvate, -HEPES, hi glucose) containing 0.5x nucleoside solution (5 μM thymidine, 15 μM of
adenosine, cytosine, guanosine, and uridine), 5% knockout serum replacement (Thermo Fisher
Scientific, 10828), 0.5x non-essential amino acid solution (50 µM of each amino acid), 1x
Insulin, Transferrin, Selenium Solution (Thermo Fisher Scientific, 41400; 1.72 µM Insulin, 68.8
nM Transferrin, 38.7 nM Sodium Selenite), and 55 µM BME.

71

Neuronal medium: DFK5 medium and Neurobasal medium (NB; Thermo Fisher Scientific,
21103049) mixed in a 1:1 v/v ratio.

Long-term medium: NB with 1x GlutaMAX (Thermo Fisher Scientific, 35050061), 1x B-27
supplement (Thermo Fisher Scientific, 17504044), and 5 ng/mL for each of brain-derived
neurotrophic factor (BDNF, recombinant human, PeproTech, 450-02: resuspended as a 10
µg/mL stock in 0.1% bovine serum albumin [BSA; MilliporeSigma, A2058] in phosphate
buffered saline [PBS]), glial cell line-derived neurotrophic factor (GDNF, recombinant human,
PeproTech, 450-10: resuspended as a 10 µg/mL stock in 0.1% BSA in PBS), and neurotrophin-3
(NT-3, recombinant human, PeproTech, 450-03: resuspended as a 10 µg/mL stock in 0.1% BSA
in PBS). 0.1% BSA was prepared by diluting powder in PBS and then filtering using SteriflipGP Sterile Centrifuge Tube Top Filter Unit (MilliporeSigma, SCGP00525).

3.3.2 ESC Maintenance

RW4 mouse embryonic stem cells (mESCs; ATCC, SCRC-1018), Hb9-puro, Chx10-purotdTomato and Evx1-PAC mESCs were maintained in T-25 flasks coated with 0.1% gelatin
(MilliporeSigma, G1393; in water) in CM containing 1000 U/mL leukemia inhibitory factor
(LIF; MilliporeSigma, ESG1106) and 100 μM β-mercaptoethanol (BME; Thermo Fisher
Scientific, 21985023) in 5% CO2 at 37°C. For passaging, mESC colonies were dissociated with
0.25% trypsin ethylenediaminetetraacetic acid (trypsin-EDTA; Thermo Fisher Scientific,
25200072) for five minutes, followed by quenching and trituration with CM. Single cells were
plated in a new flask containing CM +LIF +BME at a 1:5 ratio and grown for two days or until
~80% confluent.
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3.3.3 Design and Generation of Vectors Used to Create Evx1-PAC Selectable
mESC Line

Evx1 guide RNA vectors

A list of potential guide RNA sequences to the Evx1 locus was generated by providing a partial
Evx1 genomic DNA input sequence to the algorithm found on the CRISPOR website [189]
(results can be found here: http://crispor.org/crispor.py?batchId=mN1FkRligAThyqKv3eg3; see
Figure 3.S1). Two guide RNA oligonucleotide sequences were selected based on their proximity
to the Evx1 transcript start codon as well as low number of off-target sequences listed in
CRISPOR results.

Evx1 genomic input sequence:
5’
ctcctttcatcttcactgtggcagacgtttctatttatccacttgcgttcgccgagtggcgtcaccagcggtactgtaatgacgattgcagcagg
aggatgacagcttagaaagaagagggcaatggggcttcctcccagaggcggtgcggcacagaggagcgctcgcatcacaaggtgaccc
tagctccccactgccatctccgcggtcgccgtcgacacggcgctggggctacccggcgcctgccttgtcgccttagctcctcttctcagcca
agatcccagggagcctgggattaggagcttacttgggggttttccccctccccccctctggagagtccggggATGgagagccgaaagg
acatggttatgtttctggatgggggtcagcttggcactctggttggtaagagggtctctaatttgtccgaagccgtgagcagcccgctgcctga
accgccagagaagatggtgccccacggttgcctgagcccgcgagccggccctccgacttcccgggagcgtggcgggggaggccagg
aggaggagccggtcgatggactagcaggcagtgctgcagggctgggcgccgagccacggtctgctggagcggccatgcttggcccgg
gacccccagtcccctccgcggacagcctctctggccaagggcaacctagtagctcagacaccgaatcggatttctatgaagaaatcgaggt
gagctgcaccccagactgcgccaccgggaacgccgagtaccagcacagcaaag
3’
Legend:
Evx1 transcript start codon: ATG
Evx1 guide 21: acggttgcctgagcccgcga (reverse complement)
Evx1 guide 28: gcgagccggccctccgactt (reverse complement)

Figure 3.S1: Evx1 genomic input sequence used to generate guide RNAs
The ATG start codon is shown in red; guides were chosen partly based on proximity to start codon.
Guide RNA sequences are the reverse complement of the sequences indicated in the genomic
sequence.
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Guide RNA oligonucleotides were designed and generated according to the Joung lab gRNA
cloning protocol provided on the Addgene website [190] by annealing phosphorylated singlestranded oligonucleotide sequences (ordered from Integrated DNA Technologies [IDT]; see
Table 3.1). Briefly, equivalent molar amounts of top and bottom oligonucleotide sequence
strands were mixed in T4 DNA Ligase buffer (New England Biolabs [NEB], B0202S) including
T4 Polynucleotide Kinase enzyme (NEB, M0201S). Oligonucleotide mixtures were incubated at
37°C for 1 hour to enable phosphorylation followed by heating to 95°C for 5 minutes and
cooling at a rate of -5°C/minute to 10°C to allow annealing.

Table 3.1: Oligonucleotides and primer sequences
Oligonucleotide Name

Sequence

Evx1 guide 21 F

ACACCTCGCGGGCTCAGGCAACCGTG

Evx1 guide 21 R

AAAACACGGTTGCCTGAGCCCGCGAG

Evx1 guide 28 F

ACACCAAGTCGGAGGGCCGGCTCGCG

Evx1 guide 28 R

AAAACGCGAGCCGGCCCTCCGACTTG

5’ Evx1 homology arm F

GGGGACAAGTTTGTACAAAAAAGCAGGCTCTGTAGCTATGGATTCT

5’ Evx1 homology arm R

CTCGGTCATATTGGCAAATTAGAGACCCTC

PAC cassette F

GAGGGTCTCTAATTTGCCAATATGACCGAG

PAC cassette R

GTCTGAGCTACTAGTCTAGAACTAGTGGATCC

3’ Evx1 homology arm F

GGATCCACTAGTTCTAGACTAGTAGCTCAGAC

3’ Evx1 homology arm R

GGGGACCACTTTGTACAAGAAAGCTGGGTTCGGTCCTTTATATTC

5’ genomic Evx1 F

GGAACGGGTACTTTAGGCTC

5’ PAC insertion R

TCGTAGAAGGGGAGGTTGC

3’ PAC/Neo insertion F

TCTGGATTCATCGACTGTGG

3’ genomic Evx1 R

TTGGGACCATTTCCGACCTG

74

MLM3636 vector (Addgene, 43860) was cut with BsmBI restriction enzyme (NEB, R0580S) in
1x NEBuffer 3.1 (NEB, B7203S) for 1 hour at 55°C then deactivated at 80°C for 20 minutes.
Digested MLM3636 vector was dephosphorylated with shrimp alkaline phosphatase (rSAP;
NEB, M0371S) in 1x CutSmart Buffer (NEB, B7204S) at 37°C for 30 minutes followed by
deactivation of rSAP at 65°C for 10 minutes.

Vectors for Evx1 guide 21 and Evx1 guide 28 (see Table 3.1) were created by ligating the
annealed oligonucleotide sequences with the digested MLM3636 vector using T4 DNA ligase for
16 hours at 16°C. Ligations were transformed in DH5α E. coli and selected on 2% agar in
Lennox LB broth (MilliporeSigma, L3022) containing 50 µg/ml ampicillin (MilliporeSigma,
A0166: resuspended as a 50 mg/ml stock in water).

Evx1-PAC donor vector

PCR with Klentaq LA (DNA Polymerase Technology, 110) was used to amplify both the PACPGK-Neo cassette from existing vectors used to create other selectable lines in our lab [125,126]
as well as genomic DNA sequences flanking the Evx1 guide RNA sequences for 5’ and 3’ Evx1
homology arms using genomic DNA template from the RW4 mESC line (see Table 3.1 for
primers). The homology arm primers included attB sites to allow for Gateway recombination
cloning. Overlap extension PCR was used to amplify the 5’ homology arm with the PAC cassette
and then the 3’ homology arm. BP clonase (Thermo Fisher Scientific, 11789020) was used to
recombine the homology arm-flanked PAC overlap extension PCR product into the pDONR221
vector (Thermo Fisher Scientific, 12536017). DNA from bacterial clones selected on LB-agar
plates containing 50 µg/ml Kanamycin (Thermo Fisher Scientific, BP906: resuspended as a 50
mg/ml stock in water) were isolated using QIAprep Spin Miniprep Kit (Qiagen, 27106) and
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sequence-verified (Sanger sequencing at UT Austin core facility), then recombined into the
pWS-TK3 vector (Addgene, 20349) using LR clonase (Thermo Fisher Scientific, 11791020)
according to manufacturer instructions. Bacterial clones containing the final pWS-TK3-Evx1PAC donor vector were selected on LB-agar plates containing ampicillin and isolated using
QIAprep Spin Miniprep Kit.

3.3.4 Electroporation and Expansion of Evx1-PAC mESC Clones

1x107 RW4 mouse embryonic stem cells were dissociated with 0.25% trypsin-EDTA, quenched
with CM, and pelleted at 300xg. Two plasmid mixtures were made, one for each of the guide
RNA vectors: 10 µg of pWS-TK3-Evx1-PAC, 1 µg of SpCas9 vector (Addgene, 43945), and 1
µg of either of the MLM3636-guide RNA vectors (guide 21 or 28) were mixed with 800 µl
electroporation buffer (20 mM HEPES pH 7.5, 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, 6
mM dextrose) and used to resuspend the RW4 mESCs. Each cell mixture was loaded into a
chilled 0.4 cm electroporation cuvette (Bio-Rad, 1652081), mounted into the Gene Pulser Xcell
Eukaryotic System (Bio-Rad, 1652661), and electroporated with voltage parameter 0.23 kV and
capacitance parameter 960 µF. After pulsing, cells were quickly moved into CM +LIF +BME
and grown in a 0.1% gelatin-coated 10 cm non-tissue culture treated dish for 2 days.

From days 2 to 10, electroporated cells were grown in CM +LIF +BME with 40 µg/ml
Geneticin/G418 (Thermo Fisher Scientific, 10131027) for positive selection and 150 nM
fialuridine (FIAU; MilliporeSigma, SML0632) for negative selection; medium was replaced
every 2 days. At day 10, visible single colonies were picked and dissociated using trypsin-EDTA
into 96 well 0.1% gelatin-coated cell culture plates, quenched with CM +LIF +BME, and once
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confluent, dissociated into two wells of a 96 well plate; one well was used to genotype clones for
insertion of PAC into the Evx1 genomic locus using junction PCR (jPCR; see Table 3.1 for
primer sequences). Clones positive for PAC by jPCR were also tested by copy number assay
using qPCR with Tert (Thermo Fisher Scientific, 4458368) as the reference control, GAPDH
(Thermo Fisher Scientific, Mm00186825_cn) as the reference for 2 copies in RW4 mESCs, and
a PAC custom assay (forward sequence: GGTGCCCGCCTTCCT; reverse sequence:
CGGCGGTGACGGTGAA) using Hb9-puro mESCs as a reference for 1 copy and analyzed
using the CopyCaller v2.1 software. Clones with single copies of PAC were expanded in
different well sizes until 80% confluent in T75 flasks (Thermo Fisher Scientific, 07202000), then
cells were dissociated in trypsin-EDTA, quenched with CM, pelleted at 300xg, resuspended in
cell freezing medium (MilliporeSigma, C6295), and frozen in a Mr. Frosty freezing container
(Thermo Fisher Scientific, 51000001) at -80°C before storage in liquid nitrogen.

3.3.5 Cre Excision of PGK-Neo

In one Evx1-PAC mESC clone verified by junction PCR (jPCR) and copy number assay, the
PGK-Neo selection cassette flanked by loxP sites was excised by transfecting the mESCs with
pTurbo-Cre (a gift from Dr. Timothy Ley) using Lipofectamine 3000 (Thermo Fisher Scientific,
L3000001). The day before transfection, Evx1-PAC mESCs were dissociated using trypsinEDTA, quenched with CM, and then 5x105 cells were plated in a 6-well plate well and grown in
CM +LIF +BME. For transfection, 3.75 µl of Lipofectamine 3000, 10 µl of P3000 Reagent, 5 µg
of pTurbo-Cre plasmid were mixed in Opti-MEM medium (Thermo Fisher Scientific, 31985062)
and added to the mESC culture. Once colonies were visible, clones were picked and dissociated
into 96-well plates. Each was evenly split among two wells to test for sensitivity to G418 added
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to one of the two wells to observe cell death. Those that showed cell death were chosen for jPCR
to look for the presence of Neo in the Evx1 locus. Two clones that no longer contained the PGKNeo cassette were chosen, expanded, frozen down, and one was used for all further studies.

3.3.6 V0V IN Induction, Selection, and Long-term Culture

For V0V IN induction, mESCs were cultured as previously described [103]. Briefly, mESCs were
dissociated, pelleted, and resuspended in DFK5 medium in a 10 cm tissue culture-treated agarcoated dish for embryoid body (EB) formation. After 2 days (2-), EBs were settled and fresh
DFK5 medium was used to return EBs to the agar-coated dish. After another 2 days (4-), EBs
(2.5 ml per 10 cm plate) were settled and resuspended in 10 mL of fresh DFK5 + 1 µM all-trans
retinoic acid (RA; MilliporeSigma, R2625: resuspended as a 20 mM stock in dimethyl sulfoxide
[DMSO; MilliporeSigma, D2650]) + 100 nM purmorphamine (purm; MilliporeSigma, 540223).
After 2 days (4-/2+), medium was replaced with 10 mL of fresh DFK5 + 1 µM RA + 5 µM N-{N(3,5-difluorophenacetyl-L-alanyl)}-(S)-phenylglycine-t-butyl-ester

(DAPT;

MilliporeSigma,

D5942: resuspended as a 10 mM stock in DMSO). Induction was complete after another two
days (4-/4+), at which time cultures were dissociated with 0.25% trypsin-EDTA, quenched with
CM, passed through a 100 µm cell strainer (Corning, 352360), counted, and plated on laminincoated wells at 1x105 cells/cm2 in neuronal medium supplemented with 1x GlutaMAX, 1x B-27
supplement, and 5 ng/mL for each of BDNF, GDNF, and NT-3.

For selection conditions, cultures were exposed to 4 µg/mL puromycin dihydrochloride (puro;
MilliporeSigma, P8833: resuspended as a 10 mg/ml stock in water) in supplemented neuronal
medium. After 24 hours, medium was aspirated, cells were rinsed with NB and cultured in
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neuronal medium with supplements replaced every two days. For longer term studies, after day
12, cultures were fed with half-volume exchanges of long-term medium every two days until
their respective end points.

3.3.7 V2a IN and MN Induction and Selection
Chx10-puro-tdTomato mESCs were induced using a 2-/4+ protocol using 10 nM RA and 1 μM
purm from days 2 to 6 and 5 μM DAPT for days 4 to 6 [82]. On day 6, V2a IN EBs were settled,
induction medium aspirated, and neuronal medium with supplements was used to move EBs
back to the 10 cm dish. 2 µg/ml puro was added to the culture for 24 hours. Hb9-puro mESCs
were induced using the motor neuron (MN) 2-/4+ induction protocol using 2 μM RA and 0.5 μM
SAG from days 2 to 6 [134]. Day 6 EBs were cultured in neuronal medium with supplements
containing 4 µg/ml puro from day 6 to 7.

3.3.8 Microelectrode Array Co-cultures of Selected V0V INs with Selected
mESC-Derived V2a IN and MNs

CytoView 24-well microelectrode array (MEA) plates (Axion Biosystems, M384-tMEA-24W-5)
were used to culture 1x105 cells/array of V0V INs, V2a INs, MNs, or a combination of V0V INs
with V2a INs or MNs, V2a INs and MNs, or all three populations together. Array areas were
coated with 0.01% poly-L-ornithine (MilliporeSigma, P3655; in 10 mM borate buffer, pH 8.3)
followed by washing 2 times with excess HEPES-buffered saline solution (HBSS, pH 7.2) and
coating with 5 µg/mL laminin (mouse; Thermo Fisher Scientific, 23017015; in HBSS). To
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measure activity, CytoView plates were loaded into a Maestro Edge instrument (Axion
Biosystems) for recordings.

V0V IN induction cultures were selected on day 10 with 4 µg/ml puro in supplemented neuronal
medium for 24 hours. On day 11, selection medium was aspirated, wells were washed with NB,
and medium was replaced with supplemented neuronal medium. On day 12 of V0V IN culture,
V0V INs were lifted with Accutase solution (MilliporeSigma, A6964), quenched with CM, spun
at 400xg and resuspended in 1 mL neuronal medium with supplements. Day 6-7 selected cultures
of V2a INs and/or MNs were dissociated with 0.25% trypsin-EDTA, quenched with CM,
strained through 100 µm cell strainers, spun at 400xg, and resuspended in 1 mL neuronal
medium with supplements. All populations were then counted to achieve cell densities of 1x105
cells/10 µl drop to load onto MEA wells; for single-population MEA cultures, cells were plated
at 1x105cells/array, for double-population cultures, each population was plated at 5x104
cells/array, and for triple-population cultures, each population was plated at 3.3x104 cells/array.
After allowing attachment for 4 hours, 300 µl of long-term medium was added slowly to each
well; medium was replaced by half-volumes every 2 days.

3.3.9 Isolation of RNA, Reverse Transcription, and qPCR

To collect cultured cells for qPCR analysis, medium was aspirated and cells were detached by
addition of 0.25% trypsin-EDTA followed by quenching and dissociation in CM. Cells were
pelleted at 300xg. Medium was aspirated, and pellets were resuspended in RLT buffer as
provided from the RNeasy Mini Kit (Qiagen, 74106). Pellets were either frozen at -80°C or
immediately used with the RNeasy kit using on-column DNase (Qiagen, 79254) to isolate RNA
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per manufacturer instructions. 500 ng of RNA was reverse transcribed using the High-Capacity
cDNA Reverse Transcription Kit (Thermo Fisher Scientific, 4368813) per manufacturer
instructions.

For qPCR, a solution of ultrapure water, TaqMan Fast Advanced Master Mix (Thermo Fisher
Scientific, 4444963), a TaqMan probe against mouse β-actin as a reference gene (Thermo Fisher
Scientific, Mm02619580_g1, using VIC-MGB_PL dye), and the TaqMan probe against the
target gene using FAM-MGB dye (PAC [custom ordered]: forward sequence:
GGTGCCCGCCTTCCT; reverse sequence: CGGCGGTGACGGTGAA; Evx1:
Mm00433154_m1) was prepared and loaded into a MicroAmp Fast Optical 96-Well Reaction
Plate (Thermo Fisher Scientific, 4346906) before loading each sample in triplicate. Plates were
sealed, spun briefly to remove bubbles, and loaded into the QuantStudio 3 instrument for
measurement. The fold changes in mRNA expression levels were calculated using 2^-ΔΔCT values
with β-actin as the reference gene relative to mESCs.

3.3.10 LIVE/DEAD Staining to Determine Selection Window by Image
Analysis

Cultures were grown in 48-well plates for image analysis. To test selection, 4 µg/ml puro was
added on days 9, 10, or 11 for 24 hours followed by a rinse with NB before culture in neuronal
medium with supplements for an additional 2 days post-selection before staining and imaging.

81

The LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells (Thermo Fisher Scientific,
L3224) was used with Calcein AM at 0.4 µM ((live stain, 1:10000 dilution in PBS) and Ethidium
homodimer-1 at 1 µM (dead stain, 1:2000 dilution in PBS) to stain cultures that included
unselected cells and cells selected at different time points. Cells were incubated for 30-40
minutes before rinsing once with PBS, then imaging.

Images were analyzed using a CellProfiler pipeline [178,179] to determine the percentage of
living cells. The majority of dead cells were washed away post-selection. 4 images were taken of
each well for each condition at each time point with N = 6. The percentage of living cells was
calculated based on the count of live cells in selected wells divided by the count of live cells in
unselected wells, as all wells were plated at the same density of 1x105 cells/cm2.

3.3.11 Flow Cytometry

Day 11 cultures, both unselected and selected with 4 µg/ml puro from day 10-11, were
dissociated and spun at 400xg for 5 minutes, and pellets were fixed in 4% paraformaldehyde
(PFA; MilliporeSigma, P6148; in 0.1M phosphate buffer) for 20 minutes at room temperature.
Cells were then incubated in 2% normal goat serum (NGS; MilliporeSigma, G9023) with 0.1%
Triton X-100 (MilliporeSigma, X100) in PBS to permeabilize and block for 30 minutes at room
temperature. Primary antibodies (see Table 3.2) were diluted in 1% NGS in PBS and cells were
stained for 40 minutes at room temperature. Cells were washed 2 times for 10 minutes per wash
with PBS. Secondary antibodies (see Table 3.3) were diluted in 1% NGS in PBS and cells were
stained for 40 minutes at room temperature. Cells were washed 2 times for 10 minutes per wash
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and then resuspended in PBS before running samples on Attune NxT cytometer (Thermo Fisher
Scientific).

Table 3.2: Primary antibodies used for ICC and flow cytometry
Target

Final concentration Source, product number
or dilution used

βIII tubulin 1 µg/mL

Biolegend, 802001

βIII tubulin 1 µg/mL

Biolegend, 845501

Chx10

0.2 µg/mL

Santa Cruz Biotechnology, Inc., sc-374151

Dmrt3

2 µg/mL

Thermo Fisher Scientific, BS-4264R

En1

2 µg/mL

Developmental Studies Hybridoma Bank, 4G11

Evx1

0.5 µg/mL

Developmental Studies Hybridoma Bank, 99.1-3A2a

Hb9

2 µg/mL

Developmental Studies Hybridoma Bank, 81.5C10

Lim1

5 µg/mL

Developmental Studies Hybridoma Bank, 4F2

MAP2

1:1000 dilution

MilliporeSigma, AB5622

NeuN

1:50 dilution

MilliporeSigma, MAB377

Olig2

1:500 dilution

MilliporeSigma, MABN50

VAChT

5 µg/mL

Thermo Fisher Scientific, MA5-27662

VGLUT2

1:3000 dilution

MilliporeSigma, AB2251-I

3.3.12 Immunocytochemistry and Image Analysis

Long-term cultures in 48-well, laminin-coated plates were used for immunocytochemistry (ICC)
analysis. After aspirating culture medium, wells were rinsed with PBS, and cells were fixed in
4% PFA for 20 minutes at room temperature. Cells were then incubated in 2% normal goat
serum (NGS; MilliporeSigma, G9023) with 0.1% Triton X-100 (MilliporeSigma, X100) in PBS
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to permeabilize and block for 30 minutes at room temperature. Primary antibodies (see Table
3.2) were diluted in 1% NGS in PBS and cells were stained overnight at 4°C. Wells were washed

Table 3.3: Secondary antibodies used for ICC and flow cytometry
Targeta

Conjugated fluorophore Final concentrationb Product numberc

Guinea pig IgG Alexa Fluor 488

4 µg/mL

A-11073

Mouse IgG1

Alexa Fluor 488

2, 4 µg/mL

A-21121

Mouse IgG1

Alexa Fluor 647

4 µg/mL

A-21240

Mouse IgG2a

Alexa Fluor 488

2, 4 µg/mL

A-21131

Mouse IgG2a

Alexa Fluor 555

4 µg/mL

A-21137

Mouse IgG2a

Alexa Fluor 647

2, 4 µg/mL

A-21241

Mouse IgG2b

Alexa Fluor 488

2 µg/mL

A-21141

Rabbit IgG

Alexa Fluor 488

2, 4 µg/mL

A-11008

Rabbit IgG

Alexa Fluor 647

2, 4 µg/mL

A-21244

a

All secondary antibodies were from goat hosts

b

2 µg/ml was used for flow cytometry, 4 µg/ml was used for ICC

c

All secondary antibodies were purchased from Thermo Fisher Scientific

3 times for 10 minutes per wash with PBS. Secondary antibodies (see Table 3.3) were diluted in
1% NGS in PBS and filtered through a 0.22 µm PVDF syringe filter (MilliporeSigma,
SLGV033RS). To prevent fluorescence photobleaching of conjugated secondary antibodies,
plates were wrapped in foil while cells were incubated for 1 hour at room temperature.
Secondary antibody solutions were removed, and cells were washed 3 times for 10 minutes per
wash with PBS. Cells were then stained in 1:1000 Hoechst 33258 (Thermo Fisher Scientific,
H3569) in PBS for 10 minutes, washed once with PBS, then imaged on a DMi8 inverted
widefield microscope (Leica).
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3.3.13 Statistics

GraphPad Prism version 7 and Microsoft Excel were used for statistical analyses. In Prism,
ROUT method with Q=1% was used to remove outliers - this method initially generates a
Lorenzian distribution and uses a robust curve fit and Q as a false discovery rate to determine
outliers from the residuals of the fit, and then for the remaining data, it uses least-squares
regression to determine any additional outliers. Values are reported as means and error bars are
standard error of the mean (S.E.M.) unless otherwise stated. One-way analysis of variance
(ANOVA) using Scheffe’s multiple comparison method with 95% confidence was used to
determine significance, which is indicated in figures as follows: * for p < 0.05, ** for p < 0.01,
*** for p < 0.001, and **** for p < 0.0001, unless otherwise stated.

3.4 Results
3.4.1 Inserting PAC into a Single Evx1 Gene Locus

V0V IN marker-expressing cells and other propriospinal IN populations can be induced from
mESCs, but the resulting culture is heterogenous and can include proliferative cell types that will
dilute the post-mitotic neurons. To better characterize the derived V0V IN population and use
them in controlled in vitro investigations and potentially as a transplantable population in rodent
SCI models, a method of purifying them is desirable. To this end, a gene for an enzyme that
confers protection against puromycin (puro), puromycin N-acetyltransferase (PAC), was inserted
into the locus of Evx1, the distinguishing marker for V0V INs. The goal was to use
CRISPR/Cas9-mediated homology-directed repair (HDR) to insert the PAC selection marker
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gene into a single locus to confer puro resistance while maintaining Evx1 expression to enable
V0V IN induction (Figure 3.1).

Figure 3.1: Inserting PAC into a single Evx1 locus using CRISPR/Cas9-mediated homologydirected repair
(A) Schematic showing electroporation of mESCs to incorporate 3 plasmids: SpCas9, Evx1 guide
RNA (gRNA), and the pWS-TK3-Evx1-PAC donor vector. The donor vector contains homology arms
(5’ and 3’ HAs) against Evx1 genomic sequences flanking the cut site, PAC, floxed PGK-Neo for
positive selection, and the negative selection marker TK3. (B) Schematic showing SpCas9 being
guided to the Evx1 genomic locus by Evx1 gRNA. The Cas9 cut site is flanked by homologous
sequences to the HAs of the donor vector, which is inserted into the double-stranded break (DSB)
through homology-directed repair (HDR). Cre-mediated recombination removes the Neo cassette so
that only PAC remains in the Evx1 locus. (C) jPCR images showing the wildtype RW4 mESCs as a
control, with PAC insertion in both Evx1-PAC and Neo-excised (n.e.) Evx1-PAC, as well as presence
of Neo in Evx1-PAC and absence in Evx1-PAC n.e. mESCs. (D) Copy number assay using the
previously established Hb9-puro mESC line as a control for one copy of PAC and RW4 mESCs as a
control for two copies of GAPDH as a reference. Evx1-PAC and Evx1-PAC n.e. mESCs show one
copy of PAC. Error bars show the range of possible copies, not S.E.M.
.
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Three plasmids were electroporated into wildtype RW4 mESCs to promote HDR: one with a
guide RNA (gRNA) to direct Cas9 to an appropriate site in the Evx1 locus to create a doublestranded break (DSB), one encoding the SpCas9 enzyme, and a vector to act as donor DNA to
insert PAC into the locus during HDR (Figure 3.1A). The donor vector included homology arms
- with sequences homologous to the genomic locus of Evx1 adjacent to the guide RNA sequences
in the genome - flanking PAC and floxed PGK-Neo, a positive selection marker; the vector
backbone also included a negative selection marker, thymidine kinase 3 (TK3) to select against
random, non-HDR-mediated insertion. After Cas9 generated a DSB at the site specified by the
Evx1 gRNA, the donor vector provided the donor DNA for DNA repair mechanisms to perform
HDR (Figure 3.1B). Junction PCR (jPCR) using a primer aligned to Evx1 genomic sequence
upstream of the insertion and a primer aligned to the PAC sequence was used to confirm
insertion into the Evx1 locus (Figure 3.1C). To ensure that the primary transcript being expressed
was PAC in the generated Evx1-PAC mESCs, the floxed PGK-Neo sequence was excised
through Cre-mediated recombination; Cre was introduced by transfecting positive Evx1-PAC
mESC clones screened by jPCR and determining their sensitivity to G418 (Neomycin). G418sensitive clones were screened by jPCR using a primer aligned to Neo and a primer aligned to
Evx1 genomic sequence downstream of the cassette insertion to confirm removal of PGK-Neo
(Figure 3.1C). Using screened clones of Evx1-PAC and Neo-excised Evx1-PAC (Evx1-PAC
n.e.) mESCs from jPCR, a copy number assay was performed to ensure that only one Evx1 locus
was modified (Figure 3.1D). A single verified clone was used in all further experiments and is
hereafter referenced as Evx1-PAC in all data and discussion.
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3.4.2 Determining Puromycin Selection Window

Previously we found mESC-derived V0V IN inductions have the highest fold increase in Evx1
mRNA expression over uninduced cultures at day 8, and the greatest percentage of cells as
Evx1+/Lim1+/βIII tubulin+ neurons occurs at day 10 (Figure 2.3) [103]. As PAC is inserted into
the Evx1 locus, Evx1 gene regulatory elements drive expression of PAC, and Evx1 mRNA
expression is possibly altered. Both Evx1 and PAC mRNA expression levels were measured to
determine whether insertion of PAC resulted in its expression while maintaining expression of
Evx1 (Figure 3.2). Evx1 mRNA was found to be significantly decreased in Evx1-PAC-derived
V0V IN cultures relative to RW4-derived V0V IN cultures (Figure 3.2A). However, image
analysis comparing RW4- and Evx1-PAC-derived V0V IN cultures on day 11 showed similar
levels of Evx1+/Lim1+/βIII tubulin+ cells (Figure 3.2B), with a trend toward a greater percentage
of these cells present in Evx1-PAC-derived inductions (25.12±3.58% vs 38.53±8.16% for RW4
vs Evx1-PAC, respectively; p=0.14) demonstrating that even with a reduction in Evx1 mRNA
expression, production of V0V IN marker-expressing cells did not have a corresponding
reduction.

Selection of mESC-derived V0V IN cultures should kill mESCs and other cell types while
sparing V0V INs. This requires that PAC be expressed at a high enough level to achieve
selection. In alignment with the window of peak Evx1 mRNA and protein expression, PAC
mRNA was examined on days 8, 9, 10, and 11 in V0V IN induction cultures (Figure 3.2C). PAC
mRNA expression was found to have the highest fold increase, around 20-fold relative to Evx1PAC mESCs, at day 8. To ensure that the achieved PAC mRNA expression level was sufficient
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Figure 3.2: Determining puromycin selection window based on PAC and Evx1 expression
(A) Evx1 mRNA expression in day 8, 9, 10, and 11 V0V IN induction cultures derived from RW4 or
Evx1-PAC mESCs. N = 7-8. (B) ICC image analysis showing the percentage of cells expressing V0V
IN-markers in RW4- and Evx1-PAC-derived day 11 V0V IN cultures. N =5. (C) PAC mRNA
expression in day 8, 9, 10, and 11 V0V IN induction cultures derived from RW4 or Evx1-PAC mESCs.
N = 5-8. (D) Percentage of surviving cells after selection with 4 µg/ml puro from day 9-10, day 10-11,
or day 11-12, as determined by LIVE/DEAD image analysis (calculated relative to surviving
unselected cultures) 2 days after staining (day 12, day 13, or day 14, respectively). N = 6. (E)
Representative images of unselected cultures and cultures selected with 4 µg/ml puro in Evx1-PAC
mESCs and Evx1-PAC-derived V0V INs. The V0V IN induction was selected on day 10-11 and
imaged on day 13. Scale bar is 50 µm. For (A)-(D), error bars are S.E.M. For (A) and (C), significance
is indicated as follows: *** denotes p < 0.001 relative to other time points of the same cell line, ****
denotes p < 0.0001 relative to other time points of the same cell line, ### denotes p < 0.001 relative to
the same time point for the other cell line, #### denotes p < 0.0001 relative to the same time point for
the other cell line.
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for selection, Evx1-PAC mESC cultures and V0V IN cultures were examined for sensitivity to
puro (Figure 3.2E). The mESCs died in the presence of 4 µg/ml puro. In selected V0V IN
cultures, some living cells remained at a lower cell density relative to unselected cultures,
showing cell death of some of the heterogenous cultured cells.

After verifying that puro killed mESCs and spared some of the induced cells, the time period for
selection was established. 4 µg/ml puro was added to cultures for 24 hours on days 9, 10, or 11.
After a further 2 days of culture, selected cultures were compared to unselected control cultures
plated at the same density at the same time by LIVE/DEAD staining and imaging. A CellProfiler
image analysis pipeline was used to determine counts of living cells –only expressing LIVE stain
- and the percentage of cells surviving selection was determined by using the count of living cells
in selected cultures divided by the count of living cells in unselected cultures (Figure 3.2D).
Selection on day 10 to 11 or on day 11 to 12 yielded approximately the same survival
percentage, around 15%. Based on this survival percentage and the coinciding peak number of
V0V IN marker-expressing cells occurring at day 10, cultures were exposed to 4 µg/ml puro on
day 10-11 as “selected” cultures for subsequent experiments.

3.4.3 Examining Purity of Selected V0V IN Cultures

Selection should ideally spare only V0V INs in the induction cultures, but selection of transgenic
cell line-derived neurons by puro does not completely purify the desired population [125,126].
Evx1 is transiently expressed in vivo and in vitro, and in mESC-derived cultures, the number of
cells co-expressing Evx1 and Lim1 that are also identified as neurons from positive βIII tubulin
staining decreases dramatically by day 12 (Figure 2.3) [103]. Therefore, although some cell
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death still occurs over the next couple of days (data not shown), V0V IN induction cultures were
examined by immunocytochemistry (ICC) immediately after selection to look at V0V IN markers
on day 11 (Figure 3.3A, B) to capture the presence of Evx1+ cells.

At day 11, there were still some Evx1+/Lim1+/βIII tubulin+ co-expressing cells in both unselected
and selected cultures as measured by ICC. Selected cultures appeared to have cells expressing
higher levels of Evx1 protein based on observed intensity of staining. The percentage of V0V INmarker expressing cells was measured by flow cytometry for unselected and selected cultures
immediately after selection on day 11 (Figure 3.3E), and there was a decrease in the percentage
of Evx1+/Lim1+ cells in selected versus unselected cultures (32.04±5.04% vs 18.04±5.04% for
selected vs unselected, respectively; p = 0.062).

These heterogenous V0V IN induction cultures were previously found to have large proportions
of non-V0V INs belonging to the populations arising adjacent to V0V INs during development
(Figure 2.4) [103]. Markers for these populations were measured by flow cytometry to examine
whether they were reduced or eliminated after selection: Dmrt3 for dI6 INs, En1 for V1 INs,
Chx10 for V2a INs, Hb9 for MNs, and Olig2 for pMNs and oligodendroglial precursors were
used (Figure 3.3F). Most of these markers were expressed in very few cells, possibly due to a
high percentage of these cells having already become post-mitotic. As such, they may have
already downregulated their transiently-expressed definitive transcription factor markers, as
induction protocols for other mESC-derived propriospinal neurons yield their respective
transcription factor marker-expressing post-mitotic populations after 6 to 8 days [49,82,93,102].
For the most adjacent populations of dI6 and V1 INs, Dmrt3+ cells significantly decreased from
24.16±6.33% to 8.02±2.57% (p=0.035), while En1+ cells decreased from 1.65±0.78% to
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Figure 3.3: Selected cultures contain V0V IN marker-expressing cells and have reduced Ki67+
and other IN marker-expressing cells
(A, B) Representative images of day 11 Evx1-PAC mESC-derived V0V IN cultures stained by ICC for
V0V IN markers Lim1 (green), Evx1 (red), and βIII tubulin (blue). Hoechst stain for nuclei is shown in
montage images. (C, D) Representative images of day 16 Evx1-PAC mESC-derived V0V IN cultures
stained by ICC for proliferative marker Ki67 (green), Hoechst for nuclei (red), and neuronal marker
βIII tubulin (blue). Phase is shown in montage images. (A) and (C) show unselected cultures while (B)
and (D) show selected cultures. Scale bars are 50 µm. For each condition, magnified images (Ai, Bi,
Ci, Di) are shown adjacent to their derived images to facilitate viewing details. (E, F) Day 11 flow
cytometry analysis of selected vs unselected Evx1-PAC mESC-derived V0V IN cultures. Error bars are
S.E.M., and significance is indicated as follows: * denotes p < 0.05 between selected vs unselected
cultures for the same stain. (E) Unselected and selected samples were stained for V0V IN markers of
Evx1 and Lim1 (N = 13, 15), V0C IN markers of Pitx2 and VAChT (N = 4), neuronal marker βIII
tubulin (N = 11, 13), and proliferative marker Ki67 (N = 15, 10). (F) Unselected and selected (cont’d)
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samples were stained for markers for IN populations arising adjacent to V0V INs: Dmrt3 for dI6 INs
(N = 11, 10), En1 for V1 INs (N = 7, 10), Chx10 for V2a INs (N = 10), Hb9 for MNs (N = 9, 12), and
Olig2 for pMNs and oligodendroglial precursors (N = 7).

0.61±0.25% (p=0.161). V0V INs include a cholinergic Pitx2+ subpopulation, V0C INs, which
form monosynaptic connections with MNs. Therefore, co-expression of Pitx2 and vesicular
acetylcholine transporter (VAChT) was also measured by flow cytometry in selected cultures to
compare against unselected cultures (Figure 3.3E). There was no difference in the percentage of
cells expressing these markers, even with the measured decrease in cells expressing V0V IN
markers (6.19±2.20% in unselected vs 6.36±1.54% in selected, p = 0.952).

Proliferative cell types can dilute the post-mitotic neuronal population and result in reduced
purity over time and possibly result in teratoma formation after transplantation. Ki67 was used to
mark proliferative cells. ICC on day 16 showed few Ki67+ cells in unselected cultures (Figure
3.3C), while little to no stained cells were shown after selection (Figure 3.3D). βIII tubulin was
co-stained with Ki67, which showed that neuronal cells did not co-express Ki67, and after
selection, neurons persisted while proliferative cells were removed. Flow cytometry data of day
11 cultures showed that Ki67+ cells significantly decreased from 7.06±1.80% to 0.61±0.22%
(Figure 3E; p=0.019). βIII tubulin+ cells increased in selected cultures, although not significantly
(80.59±4.94% vs 85.54±3.80%, p=0.337). Interestingly, the percentage of neuronal cells
increased in Evx1-PAC-derived inductions compared to RW4-derived cultures, which had
61.72±7.89% βIII tubulin+ cells (data not shown; N=3, p=0.095 vs Evx1-PAC mESC-derived
βIII tubulin+ cells; also see Figure 2.3D), perhaps due to altered neuronal specification related to
reduced Evx1 expression.
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3.4.4 Observing Maturation of Long-term Selected V0V IN Cultures

To determine whether selected V0V IN cultures showed maturation over time, cells were
examined by ICC for mature neuronal markers and synaptic markers on days 16 and 22 (Figure
3.4). Fox3+ post-mitotic neuronal nuclei marked by NeuN, microtubule-associated protein 2

Figure 3.4: Long-term selected Evx1-PAC mESC-dervied V0V IN cultures show expression of
mature neuronal markers and synaptic markers
Representative images of selected cultures stained by ICC. (A, B) Glutamatergic cell type marker
VGLUT2 (green), post-mitotic neuronal marker NeuN (red), and dendritic marker MAP2 (blue). (C,
D) Cholinergic cell type marker VAChT (green), pre-synaptic marker Bassoon (red), and dendritic
marker MAP2 (blue). Hoechst is shown in montage images. Scale bars are 50 µm. For each condition,
magnified images (Ai, Bi, Ci, Di) are shown adjacent to their derived images to facilitate viewing
details. For (A) and (C), cultures were examined at day 16, and for (B) and (D), cultures were
examined at day 22.

(MAP2) as a dendritic marker of maturing neurons, and vesicular glutamate transporter 2
(VGLUT2) for glutamatergic neurons were used to stain cultures (Figure 3.4A, B). All three
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markers were found to be co-expressed in a large proportion of the cells that had survived
selection and long-term culture, with clearer processes marked by MAP2 by day 22.

Potential V0C INs were detected in selected day 16 and day 22 cultures by expression of
VAChT; these cells also showed co-expression with the pre-synaptic marker Bassoon and
dendritic marker MAP2 (Figure 3.4C, D). As flow cytometry data suggest that there are very few
or no remaining MNs in selected V0V IN cultures while Pitx2+/VAChT+ cells remained, the
observed incidence of VAChT+ cells additionally supports that there may be V0C INs present.

3.4.5 Measuring Selected V0V IN Culture Activity

Combinations of single population, double population, or triple population co-cultures of mESCderived selected cultures of V0V INs, MNs, and V2a INs were examined for electrophysiological
activity by MEA recordings. Two trials were completed to day 30, with one plate having obvious
glial presence (+glia), as medium color changed quickly at the later days of culture. Bursting
patterns at day 26 for different populations that showed bursting activity are shown in Figure 3.5.
Bursting patterns of the very robust bursts that occurred in day 26 cultures +glia are shown in
Figures 3.5A-D. V2a INs show distinct, synchronized short bursts within the network burst
(Figure 3.5A); this pattern is also observed in the MN:V2a IN co-cultures (Figure 3.5B). In
MN:V0V IN cultures, there is a longer train of bursting before any distinct, shorter bursts are
observed (Figure 3.5C). When MN:V2a IN:V0V INs are cultured together, this burst train still
occurs but is shorter and is followed by the distinct short bursts seen in V2a IN cultures (Figure
3.5D). These distinct patterns support the idea that different excitatory populations – V2a and
V0V INs – are present and communicating differently with MNs, and when all are present, both
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Figure 5: Bursting
patterns of networks
formed from
combined, selected V0V
INs, V2a INs, and MNs
(A-D) Bursting patterns
of selected IN and MN
cultures on day 26 of
Evx1-PAC mESCderived V0V IN cultures
which were surmised to
contain glia: (A) V2a
IN, (B) MN:V2a IN cocultures, (C) MN:V0V
IN co-cultures, (D)
MN:V2a IN:V0V IN cocultures. A 10 second
time period is shown,
and boxes within plots
represent Axion’s
software indication of a
network burst. (E-H)
Bursting patterns of cocultures containing day
26 Evx1-PAC mESCderived V0V INs with
little glial presence: (E,
F) MN:V0V IN coculture, (G, H) MN:V2a
IN:V0V IN co-culture.
(F) and (H) are snippets
from (E) and (G),
respectively. For (E)
and (G), a 15 second
time period is shown. In
(F) and (H), blue bars
show Axion’s software
indication of bursts
versus black bars which
are spikes without
bursting. Some
semblance of alternation
can be detected in both
co-culture conditions.
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IN populations contribute to the network circuitry. This sort of synchronized bursting was
observed less frequently, if at all, in the MEA cultures with little glial presence (not shown).
Although cultures without glia had less synchronized bursting, patterns reminiscent of alternation
occurred in cultures that contained V0V INs (Figures 3.5E-H). These “alternations” were
observed from around day 24 to around day 28.

Figure 3.6 shows activity, network, and synchrony metrics from day 22, 26, and 30 MEA
recordings. To highlight the difference in cultures with few glia versus those with surmised glial
presence, data are presented for each replicate rather than as means to maintain the differences
observed in cultures +glia versus those with no obvious glial presence. The mean firing rate
(MFR) of both MNs and V0V INs alone as well as V2a IN:V0V IN co-cultures did not increase
above what occurred at the initial plating (on day 12) over time (Figure 3.6A). Otherwise, the
general trend was that MFR increased over time, and MFR for cultures in the presence of glia
were higher than without glia. MN:V0V IN cultures had a greater MFR than the MN:V2a IN or
MN:V2a IN:V0V IN co-cultures. MN:V2a IN cultures only had a MFR above the day 12 MFR
when glia were present.

Only cultures that achieved MFR above day 12 levels also had any bursting (V2a IN, MN:V2a
IN, MN:V0V IN, MN:V2a IN:V0V IN). Co-cultures containing V0V INs +glia had a larger
number of spikes per burst which decreased over time (Figure 3.6B). Spikes per burst for V2a IN
cultures +glia and co-cultures with MNs +glia remained level over time. Burst durations for
cultures +glia also decreased or remained level (Figure 3.6C), coinciding with the reduced
number of spikes per burst over time. These data also align with the burst frequency remaining
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Figure 6: Activity and
network metrics of
different combinations of
selected V0V INs, V2a INs,
and MNs showing
functional activity of
selected neuronal cultures
(A-D) Metrics of different
populations at day 22, 26, or
30 of V0V IN culture.
Activity metrics include (A)
mean firing rate (MFR) in
Hz, (B) spikes per burst, (C)
burst duration in seconds,
and (D) burst frequency in
Hz. Network metrics include
(E) number of network
bursts, (F) number of spikes
per network burst, and (G)
network burst duration in
seconds. Synchrony metrics
include (H) the synchrony
index, a unitless
measurement indicating
perfect synchrony at 1 and
perfect asynchrony at 0. A
legend shows symbols for
each population alone,
double populations, and all
three cell types together,
both in the culture with
(open symbols, +glia) and without (closed symbols) glia: MN-blue circles, V2a IN–green squares,
V0V IN–red triangles, MN:V2a IN–cyan hexagons, V2a IN:V0V IN–orange diamonds, MN:V0V IN–
magenta hexagons, MN:V2a IN:V0V IN–gray/crossed squares.

level over time (Figure 3.6D). Of note are that by day 30, the V2a IN culture burst frequency
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increases, while the MN:V0V IN co-cultures have an increased burst duration and spikes per
burst; these data may allude to the IN populations’ roles in the network.

3.5 Discussion
CRISPR/Cas9 technology was used to generate a DSB for HDR-mediated insertion of PAC into
a single Evx1 locus. Two Evx1 gRNAs, guide 21 and guide 28, were designed and delivered to
electroporated mESCs, but the clones derived from guide 28 resulted in much higher levels of
PAC mRNA expression in the mESCs (data not shown), which made it difficult to detect a fold
change increase in PAC mRNA expression in V0V IN inductions relative to mESCs. Likely, this
would have resulted in poor selection of V0V INs from cultures and/or remaining mESCs postselection. Therefore, clones chosen for further screening were all from electroporation with guide
21, which produced little PAC mRNA in mESCs.

After insertion of PAC into Evx1, there was a significant decrease in the amount of Evx1 mRNA
expression in V0V IN inductions derived from the Evx1-PAC mESC line compared to RW4derived inductions. However, rather than a decrease in the observed protein expression, there
was a considerable, although not significant, increase in the proportion of induced cells coexpressing the V0V IN markers Evx1, Lim1, and pan-neuronal marker βIII tubulin (Figure 3.2B).
There was also an increase in the percent of βIII tubulin+ cells in Evx1-PAC mESC-derived
cultures compared to RW4 mESC-derived cultures, as measured by flow cytometry (data not
shown). This suggests that disruption of one Evx1 allele results in altered neuronal specification,
but the mechanism behind this change is unclear and requires further study. Previous work using
mutated Evx1 showed it has involvement in anteroposterior patterning through associated
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BMP/Wnt pathway signaling effects [191]. Evx1 mutation resulted in downregulated expression
of BMP and Wnt pathway genes; as the proteins of these genes are known to be involved in
dorsal IN specification [46], perhaps Evx1-PAC mESCs can more easily generate ventral IN
subtypes, resulting in the observed increase of V0V IN marker-expressing cells.

The puro selection window was determined to be 24 hours from day 10 to 11 or day 11 to 12. All
analyses for selected culture composition, maturation, and functional recordings were completed
with day 10 to 11 selected cultures. It is possible the results of these analyses would differ if day
11 to 12 cultures were examined instead, such as by allowing more time for V0C IN specification
before selecting, for example. Future work is needed to determine if the alternate selection
window changes the measured outcomes for these cultures.

Evx1-expressing cells appeared to be enriched in selected versus unselected cultures as observed
by ICC (Figure 3.3A, B). However, flow cytometry data showed that there was an obvious,
although not significant, decrease in Evx1+/Lim1+ cells in selected cultures. It is possible that the
robust Evx1 expression observed by ICC is due to those Evx1+ surviving cells expressing
relatively higher levels of Evx1 compared to others that succumbed to puro, and that the
discrepancy between ICC and flow data is due in part to this relatively higher expression as well
as the transient expression of Evx1 known to occur in these cells [56].

To further illuminate, consider the following potential explanation. On day 11, Evx1 is expressed
in about 30% of the induced cells, some with higher expression levels than others (this
percentage would be slightly higher at day 10 and lower at day 12 due to transient Evx1
expression). This is likely due to the use of EB-based inductions resulting in “waves” of V0V IN
specification, the foremost wave starting around day 8, followed by successive waves that build
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up to yield the peak of cells expressing V0V IN markers at day 10, and continue until about day
12 when marker-expressing cells wane. Of the 30% Evx1+ day 11 cells, those from earlier waves
might already be turning Evx1 expression off, thus having a concomitant decrease in PAC
expression. These cells expressing lower levels succumb to puro while those with higher
Evx1/PAC levels from waves closer to the time of selection survive. Some of the V0V INs that
survived selection might, at the time of assaying, have low Evx1 expression or have already
turned off Evx1 expression, while the ones retaining Evx1 expression have high levels of
expression. Therefore, flow cytometry measurements might not be a true representation of the
surviving percentage of V0V INs these cultures. Further work is needed to verify that the
surviving cells are truly V0V INs, perhaps by finding targets downstream of Evx1 and examining
their expression in these cells or by generating an alternative, lineage-traceable mESC line.

Although verification of selection yielding purification of cells expressing definitive V0V IN
markers was not achieved, ICC staining showed that surviving cells were largely glutamatergic,
as are V0V INs, and included some VAChT+ cells as putative V0C INs. Previous work shows the
largest proportion of non-V0V IN marker-expressing cells in these cultures are Dmrt3+ or En1+
neurons (Figure 2.4) [103]. These data are indicative that surviving neurons are V0V INs, as dI6
INs and V1 INs are both inhibitory populations [38,62].

In MEA functional studies, of the single population cultures, V2a INs were the only population
that achieved bursting. This could possibly be due to survival of other propriospinal cell types,
such as MNs, V2b INs, or even V0V INs, which arise close to V2a INs and have been shown to
be part of the heterogenous resultant mESC-derived V2a IN culture, even after selection with 2
µg/ml puro, albeit at very low percentages [82,125]. However, V2a INs purposely co-cultured
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with either V0V INs or MNs did not achieve bursting, except for with MNs when glia were
present. Co-culture with MNs +glia also did not achieve as high a level of activity as V2a INs
cultured alone, suggesting that inhibitory populations such as V2b INs are not likely to be
present, and possibly, if there are MNs in the V2a IN only cultures, the proportion of MNs must
remain low relative to V2a INs to achieve higher bursting activity. Also, previous work in our
lab showed that these mESC-derived selected V2a IN cultures could synapse with each other
[125]. Studies examining the electrophysiological characteristics of V2a INs in vivo described
three electrophysiological classes of V2a INs, and those of the same class can undergo electrical
coupling and fire rhythmically during fictive locomotion [192]. This also aligns with the
observed bursting pattern of V2a IN single population cultures having distinct, rhythmic short
bursts at the late stage of the network burst (Figure 3.5A), as well as contributing a rhythmic
bursting pattern to MN co-cultures (Figure 3.5B).

Examining recordings of the different combinations of selected V2a INs, MNs, and V0V INs
allowed some light to be shed on their role in the generated networks. Even with variable data
within and among groups, a general idea of the activity of the different populations can be
gleaned. The presence of glia appears to support network formation, as cultures with glia showed
improved maturation based on MFR, burst metrics, and greater network synchrony; these results
could be anticipated based on previous work showing glial support of network formation and
maturation [193]. The difference in bursting for cultures containing V0V INs with (Figures 3.5C,
D) versus without glia (Figures 3.5E-H) could suggest that some population of V0V IN
contributing to alternation is not as reliant on glial support for maturation, while another
population that contributes to burst trains observed in cultures +glia requires glial support for
survival and/or maturation. It is exciting to think these could be V0C INs, which are involved in
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MN output modulation [57], as the burst trains suggest some level of burst modulation through
the extended burst duration. ICC shows VAChT+ cells are present; however, further work is
needed to verify these are the cells that contribute to this bursting pattern in these cultures. More
replicates, both with and without glia, might help further elucidate MN and IN functions in MEA
networks, but a recent analysis of MEA-based data suggests that many – perhaps even an
impractical number, depending on the complexity of the culture and activity level achieved –
replicates would be needed to obtain statistically relevant data due to batch-to-batch variability
and other factors influencing MEA measurements [194].

In studies examining CPG circuitry using spinal cord preparations, the native circuitry is
organized, resulting in clear pairs of alternators, whether flexor-extensor or left-right pairs.
However, in these in vitro cultures, there are not necessarily distinct pairs but, as appears to be
the case observed in Figures 3.5F and H, there could be three or more alternators communicating
with each other. This may seem counterproductive if these cells were to be transplanted into
injured spinal cords with the aim of improving motor function, since motor functions require
pairing and additional nodes may be introduced by these cells. However, it might be possible that
the remaining organized tissue after injury would incorporate and lend organization to any
transplanted cells, especially since supportive glia and other circuitry components like inhibitory
INs may contribute to and guide their activity post-transplantation.

In this paper we have shown the successful creation of a Evx1-PAC transgenic mESC line with a
single modified locus to use as a tool in selected IN circuit studies and for transplantation studies
in rodent models. V0V IN markers were detected, although not at enriched levels after selection –
likely due to transient Evx1 expression. The surviving INs were largely neurons expressing
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glutamatergic marker VGLUT2 and showing maturation and synaptic markers in long-term
cultures. A proportion of maturing cells also showed expression of VAChT, a marker for the V0V
subpopulation, cholinergic V0C INs, which normally modulate MN output. In terms of
functionality, the selected Evx1-PAC mESC-derived V0V cultures formed connections with MNs
or V2a INs and MNs that resulted in synchronized network bursting in the presence of glia and
ostensible alternating activity in V0V IN co-cultures without glia. This transgenic mESC line is a
valuable tool for controlled experiments exploring locomotor CPG circuitry and potentially as a
therapeutic option in animal studies.
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Chapter 4: Overall Conclusions and
Discussion
The purpose of the work presented in this dissertation was to achieve a protocol and a tool that
when used in combination would provide an improved means of performing experiments using
V0V INs. The V0V IN induction protocol using a scalable, renewable source – mESCs –
generates a considerable fraction of neurons expressing V0V IN markers by day 10 of culture.
Are these true V0V INs? It is not likely that they, or any PSC-derived IN population, can truly be
considered the bona fide intended cell type, as the complex developmental environment in vivo
has not been fully captured in the simplified induction protocols developed to generate these
cells. Nor is the post-mitotic environment of the same nature as that found in vivo, which means
maturation and connectivity probably differ from the native populations. However, as illustrated
by MEA recordings using a selected population of V0V IN-induced mESCs, they contribute to
network formation resulting in bursting in MN co-cultures, showing increased synchrony and
maturation over time. ICC illustrates their expression of maturation and synaptic markers. In this
case, the original question becomes: at what point does it matter that these are not true V0V INs?
Since these murine cells will only be used in animal models, as long as they generate network
bursts and can contribute to their known roles of alternation and motor output modulation, they
have relevance for in vitro circuit examinations and therapeutic use. There is always a balance to
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consider between model or tool practicality and achieving more precise replication of the
original system.

4.1 Alternatives and Potential Modifications for V0 IN
Induction and Selectable mESC Line
The V0V IN-selectable mESC tool could absolutely be improved upon. The simplest
improvement would be to add constitutive fluorescence to this Evx1-PAC cell line so that they
can be visualized in co-cultures with other selected IN/MN populations. If MEA and calcium
imaging studies were performed in conjunction, for example, the fluorescent neurons could be
visually confirmed as performing particular activity patterns that could be compared to
electrophysiological recordings. Fluorescence would also allow for easier identification in any
future transplantation studies.

Another possible improvement would be to generate an alternate, lineage-traceable/selectable
cell line, which would require a slew of experimental design considerations like which safeharbor locus to choose, which and how many recombinase system(s) to use, inducibility, etc. A
simple example would be to insert Cre into the Evx1 locus and insert floxed-stop PAC and/or
reporter fluorescence into Rosa26. As Evx1 is expressed, Cre would recombine out the stop so
the selective marker would be constitutively expressed (not reliant on transient Evx1 expression,
thus sustaining selectability). However, it is unknown whether Evx1 is expressed in any of the
cells at an earlier time point during induction before day 6 in EBs (Figures 2.S1, 2.2), which
would also become resistant to puro. It might be better to have an inducible Cre, like CreERT2,
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so that when V0V INs are forming, Evx1 will drive expression of Cre if tamoxifen is added to the
culture medium.

The Hb9-puro mESC line generated in our lab used Hb9 enhancer elements [134], previously
shown to drive lacZ expression in MNs [195], to drive expression of PAC rather inserting PAC
into the Hb9 locus, thus maintaining both, normal Hb9 alleles. This seems ideal for a tool used to
generate selected Hb9+ MNs. Hb9-puro mESC-induced MNs have a higher fold increase of PAC
mRNA expression (around 100 fold, data not shown) relative to their parental mESCs compared
to Evx1-PAC mESC-derived inductions (around 20 fold), and they display very robust selection.
Conserved Evx1 enhancers were discovered and shown to drive GFP expression in different
species including mice (though with some leakage to other IN populations like V2a INs) [196].
Perhaps Evx1 enhancers could be used to drive expression of PAC. This is another possible
alternative to generate a selectable Evx1 line, as the current method disrupts normal Evx1 mRNA
expression (Figure 3.2A) and could ideally express a higher level of PAC mRNA (Figure3.2C),
enhancing selection. However, it is unclear whether this approach would be advantageous in V0V
INs, as there was a slight increase in the proportion of Evx1+/Lim1+ cells when one allele was
disrupted by PAC insertion (Figure 3.2B).

Originally, the intended cell line was a Dbx1-PAC mESC line to derive all V0 INs, with the
potential to direct differentiation toward an increased proportion of V0V or V0D INs. However,
the produced cell line did produce sufficient PAC expression in the induced cells to enable their
survival post-selection (data not shown). This might have been due to somewhat low Dbx1
mRNA expression in the induced cells (Figure 2.2C), and since we were unable to improve Dbx1
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mRNA expression through the parameters tested (Figure 2.2E), this cell line was not useful for
V0 IN selection.

It is possible that altering some of the V0V IN protocol parameters would improve the yield of
V0V IN marker-expressing cells. We did not test whether other concentrations of purm (100 nM
was chosen due to the observed threshold effect on Dbx1 mRNA expression in Figure 2.2E)
would change either Evx1 mRNA expression or the percent of Evx1+ cells in inductions. Also,
the effect of adding DAPT and/or purm on the generation of V0V IN subpopulations was not
examined, so it may be possible to modify the protocol to better specify the Pitx2+ V0C or V0G
IN populations.

4.2 Future Work
More work should be done to verify that the largely glutamatergic population observed in longterm selected cultures are V0V INs. Whole-cell patch clamp electrophysiological studies are
important to complete for determination of cell phenotypes. However, no electrophysiological
characteristics have been reported for the V0V INs on a cellular level, so this might not be the
best way to confirm their identity when there is currently nothing for comparison. There have
been whole-cell recordings from Dbx1+ cells of the pre-Bötzinger complex and reticular
formation involved in inspiratory function [197,198], so some parallels might be drawn from
such information. If one were to use a lineage-traceable mouse for V0V INs (Evx1-Cre mice –
not currently available - crossed with a tdTomato reporter, for example), they could first obtain
recordings from traced V0V INs to use as a comparison. These traced neurons could also be
isolated by FACs to use in transcript- or proteomics. If cells were collected around the time of
108

V0V IN specification, -omics could reveal possible downstream Evx1 targets as potential markers
of V0V INs after Evx1 is no longer expressed, and these cells could also be used as a comparison
to selected Evx1-PAC mESC-derived V0V INs collected in the same way to help verify their
identity.

A highly glutamatergic, putative V0V IN culture as a product of the work presented herein can be
used to aid in investigations into CPG circuitry in vitro. Combining INs of different
neurotransmitter phenotypes at different ratios and incorporating genetically modified cells that
can be activated or deactivated are avenues that can be explored to elucidate the contribution of
the composite populations. For example, if the co-culture of MN:V2a IN:V0V IN was repeated
but using chemogenetic or optogenetic modifications to control cell activity, this could help
determine what role each cell type is playing in the network. The effector neurons could also be
used with neurotransmitter ant/agonists to determine the connectivity of the cells in the network.

Having a V0V IN selectable mESC line in hand will enhance studies into SCI therapies. As
previously mentioned, combinatorial strategies that address various aspects of the injury are
likely the most effective therapies. Our lab has been examining using hyaluronic acid hydrogels
to deliver neurotrophic factors to enhance neuronal survival and outgrowth, as well as mESCderived astrocyte extracellular matrix [199] to support transplanted neurons and improve axon
growth. These together with mESC-derived IN populations involved in locomotor circuits make
a promising therapy for future study to improve motor function in an animal SCI model.
Currently, we can derive and select excitatory INs and MNs from mESCs, and we are working
on also obtaining inhibitory IN populations. If transplanted together, it might be possible to
further improve recovery post-SCI over only transplanting excitatory phenotypes, as inhibitory
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subtypes can reduce pain [200], bladder dysfunction [201], and potentially spasticity that may be
caused by hyperexcitability due to uncontrolled activation by excitatory phenotypes [202]. Both
excitatory and inhibitory subtypes are important in normal locomotor CPG circuitry, so it is
plausible that using them in combination would help recover more normal CPG functions. Future
work may find a method of specifically identifying and isolating the inhibitory V0D INs, in
which case, the protocol developed from the work presented in this paper may be modified to
obtain these cells for incorporation in in vitro and in vivo models. Investigating whether
transplantation of V0V INs improves functional outcomes post-SCI was a goal that I was unable
to personally perform experiments to complete, but I would still like to see the outcome of such a
study. If I may be “cheesy” with a mouse joke: improved motor function post-SCI in rodent
models would be one small step for mice, one giant leap for mankind! That might be
exaggerating, but it is an exciting prospect nonetheless.
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